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The IkappaB kinase epsilon (IKKepsilon, IKKi, IKBKE) is both a regulator of innate 
immunity and a breast cancer oncogene that is amplified and overexpressed in ~30% 
of breast cancers. IKKepsilon promotes malignant transformation through the 
activation of NF-kappaB signaling. In addition, breast cancers that harbor 
amplifications in the IKBKE gene are dependent on IKKepsilon protein expression 
for survival. IKKepsilon has been characterized as a non-canonical inhibitor of 
kappaB kinase (IKK) that activates both the interferon response pathway and NF-
kappaB signaling in innate immunity. In this dissertation, I explore both the 
regulation and effectors of the IKKepsilon kinase in the context of malignant 
transformation. I found that IKKepsilon is modified and regulated by K63-linked 
polyubiquitination, a proteasome- and degradation-independent form of 
ubiquitination, at Lysine 30 and Lysine 401.  This modification is essential for 
IKKepsilon-induced kinase function and IKKepsilon-mediated NF-kappaB activation 
and malignant transformation. Furthermore, I identified TRAF2 as the K63 ubiquitin 
E3 ligase that associates with and modifies IKKepsilon. I also found that TBK1, a 
close family member of IKKepsilon, is also regulated by K63-linked ubiquitination. 
In collaborative work, we used an unbiased positional scanning peptide library screen 
to identify two novel downstream targets of IKKepsilon phosphorylation in the 
 iii 
 iv 
context of cancer. Specifically, we found IKKepsilon phosphorylates the tumor 
suppressor CYLD at Serine 418. CYLD phosphorylation at Ser418 downregulates its 
deubiquitinase activity and is necessary for IKKepsilon-driven transformation. 
IKKepsilon also phosphorylates TRAF2 at Serine 11. This activity promotes K63-
linked TRAF2 ubiquitination, NF-kappaB activation and is also essential for 
IKKepsilon-transformation. In addition, breast cancer cells that depend on 
IKKepsilon expression for survival are also dependent on TRAF2. Together, these 
observations define an oncogenic network that promotes NF-kappaB-mediated cell 
transformation through the K63-linked ubiquitination of IKKepsilon and subsequent 
phosphorylation of two novel substrates, TRAF2 and CYLD. 
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Nuclear factor B (NF-B) is a central transcriptional regulator of many 
important biological processes including innate immunity, inflammation, cell 
proliferation and apoptosis [1-4]. These NF-B-driven processes have also been defined 
to be important hallmarks of cancer pathogenesis [5, 6]. As a result, aberrant NF-B 
signaling has been linked as the mechanistic basis for many cancers either due to aberrant 
NF-B activation in the tumor microenvironment, which leads to inflammation, or 
dysregulation of specific NF-B pathway proteins within the tumor itself. 
The NF-Bs are a family of proteins that were initially characterized due to their 
interaction with the immunoglobulin light-chain enhancer in B cells [7]. The NF-B 
family of transcription factors is composed of five proteins: RelA(p65), RelB, c-Rel, 
p105/p50(NFB1) and p100/p52(NFB2) [8].  These proteins share a conserved Rel 
homology domain (RHD), a ~300 amino acid domain that conveys DNA binding 
specificity. A subset of the NF-B proteins – RelA, RelB and c-Rel – also share a C-
terminal transactivation domain [9]. p105(NFB1) and p100(NFB2) are synthesized as 
large precursors that undergo processing by degradation to become their smaller, active 
forms: p50 and p52 respectively [10]. The processing of p105 and p100 is an ubiquitin-
proteasome pathway mediated process that results in the specific degradation of the C-
terminal ankyrin repeat (AR) containing portion of the precursor.  In their active forms, 
NF-B proteins form homo- and hetero-dimers to act as DNA-binding transcription 
factors and promote the activation of downstream targets [11, 12]. 
The NF-B proteins are bound and kept inactive in the cytoplasm by a family of 
NF-B-binding proteins known as the inhibitors of NF-B (IBs). The activation of the 
NF-B pathway by a variety of proinflammatory stimuli and cytokine receptors results in 
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the ubiquitin-mediated degradation of the IB proteins and subsequent release and 
translocation of the NF-B dimers into the nucleus [12]. The ubiquitination of the IB 
proteins is triggered by a phosphorylation event that is mediated by a collection of 
inhibitor of B kinases (IKKs). The IKK family of proteins include the catalytically 
active IKK (IKK1), IKK (IKK2), IKK (IKK-i), TBK1 (NAK) and the catalytically 
inactive IKK (NEMO). It is the differential regulation of these IKK proteins that allows 
for the fine-tuned control of the NF-B response pathway to various stimuli. 
Various types of ubiquitination also play important and differing roles throughout 
the process of NF-B signaling [13]. Ubiquitin is a 76 amino acid covalent protein 
modification that is attached to substrates through a three-enzyme cascade. First, the 
ubiquitin-activating enzyme (E1) uses ATP to forms a thiol-ester bond between the C-
terminal glycine of ubiquitin and the active-site cysteine of the E1. This activated 
ubiquitin is then transferred to the cysteine of an ubiquitin-conjugating enzyme (E2), 
resulting in the formation of an E2-ubiquitin bond. In the last step of the process, the 
ubiquitin ligase (E3) enzyme transfers the charged ubiquitin from the E2 to the substrate 
by forming an isopeptide bond between the C-terminal glycine of ubiquitin and the -
amino group of a lysine residue on the substrate [14]. Ubiquitin itself contains seven 
internal lysines (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63) and polyubiquitin 
chain formation can occur from any one of these seven lysines [15, 16]. In addition, 
recent work has also characterized Met1 linear polyubiquitination, which is the formation 
of a head-to-tail polyubiquitin chain [17, 18]. The linkage type of the polyubiquitin chain 
can result in very different fates for the ubiquitinated substrate. To date, only 
Lys11(K11), Lys48(K48), Lys63(K63) and Met1 polyubiquitination has been observed at 
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a significant level in eukaryotic cells, though polyubiquitination of all seven linkage 
types is possible in vivo [19, 20]. K48-linked polyubiquitination is the most well-studied 
and well-known type of ubiquitin linkage and results in the canonical proteasome-
mediated degradation of the substrate [21, 22]. K11-linked ubiquitination occurs at a very 
low frequency in mammalian cells and seems to mostly recapitulate the effects of K48-
linked ubiquitination [16]. K63- and Met1- linked polyubiquitination are thought to 
positively regulate their protein targets by recruiting other ubiquitin-binding proteins and 
further activate downstream signaling [23, 24]. K48-, K63- and Met1-linked 
polyubiquitination have all been shown to play essential roles in both the positive and 
negative regulation of the NF-B pathway [18, 25-28]. 
 
CANONICAL AND NON-CANONICAL NF-B SIGNALING 
The NF-B signaling pathways can be broadly classified as canonical and non-
canonical depending upon whether a NEMO-dependent IKK signal cascade is involved 
(canonical).  In addition, canonical NF-B signaling generally involves the release of pre-
existing NF-B dimers from IBs while non-canonical NF-B signaling results in the 
novel synthesis of p100 and RelB (p52:RelB) dimers and is IB independent [9, 29]. 
Both pathways are graphically illustrated in Figure 1.1. 
 
CANONICAL NF-B SIGNALING 
The canonical pathway is activated in response to cytokine receptors including TNF-
 receptor (TNFR), IL-1 receptor (IL-1R), Toll-like receptors (TLRs) and antigen 






































Figure 1.1.Canonical and non-canonical NF-κB activation. In the canonical NF-κB 
pathway (left), stimulation of proimflammatory receptors leads to eventual activation of 
the IKK complex, which in turn phosphorylates IκB proteins and targets them for K48-
linked polyubiquitination and proteasome-mediated degradation. This frees the p50/p65 
NF-κB dimer to enter the nucleus and activate gene transcription. In the non-canonical 
NF-κB pathway (right), stimulation of a subset of receptors, including the BAFF and 
CD40 receptors, results in the eventual stabilization of the NIK kinase which allows for 
IKKα activation. IKKα phosphorylates p100, resulting in its K48-linked ubiquitination 
and proteasome-mediated processing to p52. The free p52/Rel-B dimer then translocates 
into the nucleus to activate gene transcription. 
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ultimately converges upon the activation of the IKK complex. The IKK complex is 
composed of three main components: IKK, IKK, and NEMO [30]. Activation of the 
IKK complex involves the recruitment of several ubiquitination enzymes and ultimately 
results in the activation of IKK by phosphorylation at serines 177 and 181 [31].  
Currently, there are three known pathways for IKK activation that are differentially 
utilized depending on the receptor activation pathway. TNFR activation results in the 
recruitment of the E2 ubiquitin enzyme, UbcH5, and the E3 ubiquitin ligase, cIAP1. The 
recruitment of this E2/E3 complex results in the polyubiquitination of RIP1 by various 
ubiquitin chain linkages [32, 33]. This polyubiquitination recruits the TAB/TAK1 and 
IKK complexes together and allows for TAK1 to phosphorylate and activate IKK [34]. 
Alternatively, the bringing together of several IKK complexes can also lead to TAK1-
independent trans-phosphorylation and activation of IKK. Another pathway of IKK 
activation has been recently described to involve the formation of Met1-linked linear 
polyubiquitination. In TNFR signaling, TRADD, TRAF2 and cIAP1/2 recruit the linear 
ubiquitin ligase complex, LUBAC [27]. LUBAC catalyzes the linear Met1-linked 
ubiquitination of NEMO, resulting in trans-autophosphorylation and activation of IKK 
[28]. Finally, in the third pathway of activation usually seen in IL-1R and TLR signaling, 
the E2/E3 complex of Ubc13/TRAF6 is recruited to form K63-linked ubiquitin chains on 
IRAK1 [35]. This allows for TAK1 and IKK recruitment to IRAK1, leading to the 
phosphorylation and activation of IKK by TAK1. 
Upon IKK activation, the IKK complex phosphorylates IB at serines 32 and 36, 
which leads to the subsequent K48-linked polyubiquitination of lysines 21 and 22. This 
combination of modifications results in the degradation of IB via the proteasome [36]. 
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In canonical NF-B signaling, the main NF-B dimers are formed between the 
transactivating domain-containing RelA and c-Rel together with the transactivating 
domain-lacking p50 [9]. Upon degradation of IB, the p50/p65 dimers are free to 
translocate into the nucleus where they can influence the gene transcription of 
downstream targets. Interestingly, one of the genes that is upregulated in this pathway is 
IB itself. This allows for the pathway to be rapidly shutoff in the absence of persistent 
stimulation. The canonical NF-B pathway is also negatively regulated by A20, which is 
simultaneously a K48-linkage specific E3 ligase and a K63-linkage specific 
deubiquitinase (DUB) [37]. 
 
NON-CANONICAL NF-B SIGNALING 
The most well-studied non-canonical NF-B pathway is activated in response to a 
subset of the TNF ligands including, BAFF, CD40 and lymphotoxin- [38]. This 
pathway is NEMO-independent and is ultimately regulated by an upstream signaling 
complex that involves cIAP1/2, TRAF2, TRAF3 and NF-B-inducing kinase (NIK) [39]. 
The NIK protein is continuously synthesized but is constitutively degraded through K48-
linked ubiquitination. In the non-canonical NF-B pathway, receptor stimulation initiates 
TRAF2 activation, which results in the recruitment and K63-linked ubiquitination of 
cIAP1/2. The activated cIAP1/2 and TRAF2 is then recruited into complex by TRAF3. 
This results in TRAF3, itself, undergoing K48-linked ubiquitination by cIAP1/2 and 
subsequent degradation [40]. Without TRAF3, NIK is no longer degraded, allowing for 
the accumulation of NIK protein [41, 42]. NIK then phosphorylates and activates IKK, 
which promotes the IKK-mediated phosphorylation of p100 [39, 43, 44]. 
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Phosphorylation of p100 leads to the proteasome-mediated processing of p100 to the 
active p52, which in complex with RelB is liberated to translocate into the nucleus and 
activate downstream NF-B effectors. 
 
IKK AND TBK1 
Aside from IKK and IKK, there exist two other catalytically active IKK proteins: 
IB kinase  (IKK, IKK-i, IKBKE) and TANK-binding kinase 1 (TBK1, T2K, TBK1). 
Two groups independently identified IKK at the same time. The first utilized a 
suppression subtractive hybridization screen to identify IKK as an LPS-inducible gene 
in mouse macrophages [45]. The second found IKK to be part of a novel PMA-inducible 
IB kinase complex that is capable of NF-B activation [46]. Around the same time, 
TBK1 was also identified as a binding partner for TRAF-associated NF-B activator 
(TANK) that, together with TRAF2, activates NF-B in a kinase-dependent manner [47]. 
IKK and TBK1 share 27% identity to the canonical IKK and IKK proteins [39, 
45, 47]. However, they share 49% identity and 65% similarity to one another [48]. Both 
proteins are comprised of an N-terminal kinase domain, an ubiquitin-like domain, an 
ubiquitin-binding domain, and C-terminal leucine-zipper (LZ) and helix-loop-helix 
(HLH) regions [48]. Both kinases also contain a coiled-coil multimerization domain, 
which allows them to form homo- and hetero-dimers with one another. IKK is 
specifically expressed in a subset of tissues that are important for immune function: the 
thymus, spleen, peripheral blood leukocytes, pancreas and placenta [45]. TBK1, on the 
other hand, is ubiquitously expressed throughout all organ systems [47]. 
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IKK AND TBK1 IN INTERFERON SIGNALING 
TBK1 and IKK play an essential role in the interferon response pathway to viral 
challenge [49, 50]. The interferon response pathway is normally triggered by recognition 
of viral dsRNA by TLRs. TLR activation results in the recruitment of a complex 
containing IKK, TBK1, TANK and TRAF3 [51]. Activated IKK and TBK1 further 
phosphorylate a set of interferon regulatory factors (IRFs), IRF3 and IRF7 [52-54]. 
Phosphorylation of the IRFs allows them to dimerize and translocate into the nucleus 
where they can promote the transcription of proinflammatory and antiviral genes 
including interferon- and - (IFN and IFN) [55, 56]. 
Aside from TLR-induced signaling, IKK and TBK1 can also be activated in a TLR-
independent manner. The recognition of viral dsRNA and dsDNA by DNA- and RNA- 
sensing proteins such as RIG-I, MDA-5, and DAI can lead to IKK-mediated NF-B 
activation [57-62]. In addition, IFN itself can also stimulate IKK binding to a large 
interferon activating complex known as ISGF3, resulting in the IKK-dependent 
activation of a subset of interferon response genes [63]. IKK is also shown to play a 
critical role in the balance between activation of the type I and type II (IFN-I and IFN-II) 
interferon signaling pathways through ISFGF3[64]. ISGF3 is a multimeric transcriptional 
activation complex that is composed of STAT1, STAT2, and IFN regulatory factor 9. 
IFN-II promotes the homodimerization of STAT1, resulting in the formation of the 
gamma-activated factor (GAF) complex. ISGF3 and GAF differentially control the 
transcription of IFN-I and IFN-II response genes to activate distinct sets of antiviral 
genes. IKK has been shown to phosphorylate STAT1, which prevents its dimerization 
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and subsequent GAF formation. This allows IKK to control the balance of IFN-I and 
IFN-II signaling by differential activation of ISGF3 and GAF [64]. 
TBK1 and IKK each bind several different proteins. Like the canonical IKKs, the 
kinase activity of TBK1 and IKK is increased when they are a part of a larger high-
molecular-weight complex. TBK1 and IKK have been shown to complex with a variety 
of scaffolding proteins and other enzymes, including NAP1, SINTBAD, MAVS, TANK, 
TRAF2, TRAF3 and TRADD to mediate interferon activation [65-69]. The composition 
of the protein complex differs depending on the stimulus, indicating that IKK and TBK1 
can be modulated and activated differentially depending on protein complex composition 
and formation [48]. 
 
IKK AND TBK1 IN NF-B SIGNALING 
 TBK1 and IKK are classified as non-canonical NF-B activators due to their 
ability to catalyze the phosphorylation of IB in a NEMO-independent manner. In the 
canonical pathway, IB requires two phosphorylation events at Ser36 and Ser32 to be 
targeted for degradation. IKK preferentially phosphorylates IB Ser36 [45, 46]. On the 
other hand, TBK1 preferentially phosphorylates IB Ser32 [47, 70]. Interestingly, 
overexpression of IKK alone results in the reduction of IB protein levels, suggesting 
that perhaps Ser36 phosphorylation alone is sufficient to induce IB degradation. Or, an 
alternative possibility is that IKK and TBK1 are able to recruit a canonical IKK protein 
to mediate the phosphorylation and degradation of IκB [71, 72]. 
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 TBK1 and IKK are also capable of directly phosphorylating some of the NF-B 
transcription factors. IKK and TBK1 have been shown to work with the canonical 
IKK/ kinases to phosphorylates RelA(p65) at Ser536 at a basal stimulus-free level [73, 
74]. This basal RelA phosphorylation is believed to be important for the recruitment of 
basal transcriptional machinery to the interleukin-8 promoter. Another NF-B 
transcription factor, cRel, has also been shown to be a kinase target of TBK1 and IKK. 
This phosphorylation of cRel is sufficient to promote nuclear translocation, but does not 
further activate downstream NF-B activity [75].  
 
DISTINCT ROLES OF IKK AND TBK1 
 Despite their similarity, TBK1 and IKK also each have a distinct set of non-
overlapping targets. TBK1 is known to phosphorylate and activate IKK at Ser177 and 
181, resulting in the activation of the canonical NF-B pathway [70]. Also, in the context 
of innate immunity signaling, TBK1 phosphorylates Sec5 and DDX3X to induce the 
interferon response [76, 77]. On the other hand, IKK has been shown to uniquely 
phosphorylate RelA at Ser468 to facilitate NF-B signaling, and also STAT1 in the 
context of ISGF3-dependent interferon activation [63, 78]. 
 To further support the idea that TBK1 and IKK play distinct though related roles, 
generation of the Tbk1-/- and Ikbke-/- genetic knockout mice showed that these two mouse 
models also have distinct phenotypes. Tbk1 deficient mice are embryonic lethal and die 
after E14.5 due to liver degeneration [79, 80]. This phenotype is also prevalent in NEMO, 
IKK and RelA deficient mice, indicating that TBK1 may play a role in the same 
pathway as these canonical NF-B pathway effectors. Ikbke deficient mice, on the other 
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hand, are viable. They are unable to effectively mount the interferon response to viral 
infection, but are otherwise normal when unperturbed [80]. Interestingly, both the Ikbke 
and Tbk1 deficient mice are relatively normal in the context of NF-B induction and 
signaling. This genetic evidence indicates that, although TBK1 and IKK are capable of 
NF-B induction, their roles are non-essential to the proper activation of this pathway. 
On the other hand, TBK1 and IKK are critical for the proper stimulation of the 
interferon response pathway.  
 
NF-B ACTIVATION IN CANCER 
 Aside from its normal role in the activation of the proinflammatory response to 
pathogenic challenge, the NF-B pathway has also been implicated as the mechanistic 
link between inflammation and cancer [81-83]. 
 Inhibition of various canonical NF-B pathway effectors has been shown to 
decrease disease progression in several inflammation-associated cancer models. In the 
colitis-associated cancer (CAC) mouse model [84], the canonical NF-B kinase, IKK, 
was shown to play an essential role for disease progression in two distinct cell types [85]. 
Deletion of IKK in the malignant enterocytes activated the anti-apoptotic genes to 
suppress the elimination of these cells. In addition, deletion of IKK in the myeloid 
microenvironment cells promoted the secretion of various cytokines that supported the 
growth of the malignant enterocytes. The overall result was that IKK deletion resulted 
in a ~80% decrease in tumor incidence in the CAC mouse model. In an Mdr2-knockout 
inflammatory hepatocellular carcinoma mouse model [86], the introduction of the NF-B 
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canonical pathway super repressor into hepatocytes inhibited tumor progression and 
induced apoptosis [87]. Similar to the CAC model, the microenvironment endothelial 
cells secrete TNF- to support the growth of these malignant hepatocytes. As a result, 
blocking TNF- signaling was sufficient to inhibit NF-B activation in the malignant 
hepatocytes. In both of these examples, aberrant NF-B signaling plays both a cell-
autonomous and a cell-non-autonomous role in the promotion of the disease phenotype. 
Within the tumor cell itself, NF-B activation promotes an anti-apoptotic phenotype; 
while in the microenvironment, NF-B activation promotes the secretion of extracellular 
factors to promote cell survival and growth of the tumor cells. 
 Aberrant activation of NF-B pathway effectors within the tumor cells was first 
observed in blood cancers. For example, NFKB2 is commonly involved in translocations 
in hematological malignancies [88, 89]. Upstream mutations that lead to NF-B 
activation are common in MALT lymphomas [90]. Activating mutations in Carma-1 and 
MyD88, which lead to the aberrant activation of NF-B, have been detected in B cell 
lymphomas [91, 92]. In multiple myeoloma, many NF-B pathway mutations have been 
observed including mutations in the IKK proteins (IKBKB), TRAF adaptor proteins 
(TRAF2, TRAF3), and NF-B transcription factors (NFKB2), as well as mutations that 
lead to the constitutive activation of NIK [42, 93-96]. 
 However, aberrant NF-B pathway activation is most commonly observed in 
solid tumors deriving from epithelial cells. Mutations in IKKA and IKBKB have been 
found through genomic sequencing of breast and prostate cancers [97, 98]. Aberrant 
IKK signaling has been shown to promote the self-renewal of breast cancer progenitors, 
play a role in the tumor-promoting effects of progesterone, as well as promote the 
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metastatic spread of breast cancer [99-102]. In addition, breast cancer cell lines and 
transformed mammary epithelial cells have been shown to have high levels of nuclear 
NF-κB/Rel dimers as compared to normal breast tissue, implicating a role for NF-B 
activation in breast cancer. A large scale study that interrogated copy number alterations 
in 3131 human cancer tissues also identified significant somatic copy-number alterations 
of many NF-B effectors including TRAF6, IKBKB, IKBKG, IRAK1 and RIP1 in 
epithelial cancers [103]. 
 
IKK AND TBK1 IN CANCER 
 In addition to canonical NF-B effectors, other recent studies have suggested that 
the non-canonical IKKs, IKK and TBK1 may also play a role in driving NF-B 
activation in cancer. 
 
IKK IN CANCER 
 IKK was first implicated in cancer when it was identified to be overexpressed in 
human breast cancer samples, breast cancer cell lines, and DMBA-induced mouse 
mammary tumors [71]. In this study, IKK was overexpressed in four out of six primary 
human breast cancer samples. In breast cancer cell lines, IKK was expressed at higher 
levels in MDA-MB 231, Hs578T, MDA-MB 468 and T47D cells as compared to 
untransformed MCF10F breast epithelial cells. In addition, six out of seven DMBA-
induced mouse mammary tumors exhibited higher levels of IKK expression as 
compared to the normal mouse mammary tissue. This study also showed that IKK 
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expression was increased in the mammary tumors derived from two mammary-specific 
transgenic mouse models, MMTV-CK2 and MMTV-c-rel. Ectopic expression of CK2 
in NIH 3T3 mouse fibroblasts, MCF10F and HEK293T cells induced the expression of 
IKK and chemical inhibition of CK2 in breast cancer cell lines that overexpress IKK 
showed a decrease in IKK expression. These observations suggested that CK2 may play 
a role in the regulation of IKK [71]. Another study found IKK protein levels to be 
elevated in a panel of prostate and breast cancer cell lines [104]. In this study, IKK was 
shown to catalyze the basal phosphorylation of RelA at Ser536. The phosphorylation was 
shown to be constitutive, non cytokine-induced, and was proposed to play a role in the 
transactivation of NF-B [104]. These two studies implicated a role for IKK in breast 
cancer. 
 In 2007, IKBKE, was shown to be a breast cancer oncogene through the 
integration of three functional genomics approaches [72]. In a gain-of-function approach, 
Boehm et al. utilized a human epithelial cell transformation model in which 
transformation was driven by a combination of activated MEK and activated AKT. 
Through a comprehensive kinase screen, IKBKE was identified as capable of replacing 
AKT in this model to induce malignant cell transformation as assessed by soft agar 
colony formation and tumor formation in immunocompromised mice. In a second 
approach, Boehm et al. utilized a loss-of-function screen to identify specific genetic 
vulnerabilities of breast cancer cell lines and again found IKBKE to be an essential gene 
for breast cancer survival. Finally, in the third approach, IKBKE was found to be 
amplified in 8 out of 49 (16.3%) of breast cancer cell lines and ~30% of primary breast 
cancer tumors. Taken together, the intersection of these three approaches identifies 
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IKBKE as an essential breast cancer oncogene that is significantly amplified and 
overexpressed in breast cancer cell lines and tumors. In this study, IKK-transformed 
human mammary epithelial exhibited increased expression of NF-B response genes and, 
importantly, IKK-mediated malignant cell transformation was blocked by the expression 
of the NF-B super repressor. In contrast, suppression of IRF3 and IRF7 by shRNA 
expression did not affect the ability of IKK to mediate transformation. These data taken 
together suggest that the mechanism of IKK-mediated transformation is through its role 
as an NF-B activator and is independent of its role in the interferon response pathway 
[72]. 
 Although IKBKE copy number gain does not correlate with estrogen receptor 
(ER) or Her2/Neu status [72], one study has shown that IKK phosphorylates ER- and 
contributes to tamoxifen resistance in breast cancer [105]. Guo et al. showed that IKK 
phosphorylates ER- at Ser167 both in vitro and in vivo and that this phosphorylation 
results in the transactivation of ER. As a result of this phosphorylation, cyclin D1, a 
major ER target, is upregulated. In addition, this study showed that high expression of 
IKK induces tamoxifen-resistance, and that suppression of IKK in these cells resulted 
in increased tamoxifen-sensitivity [105].  
 In addition to breast cancer, IKK has also been shown to have a prognostic role 
in several other cancer types including ovarian cancer, prostate cancer, glioma, pancreatic 
ductal adenocarcinoma, clear cell renal cell carcinoma, and non-small cell lung cancer 
[106-111]. In prostate cancer, a recent study surveyed IKK expression via 
immunostaining in paraffin-embedded prostate tissue microarrays. The investigators 
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surveyed both normal tissue (47 normal tissues, 53 non-malignant tumor-adjacent tissues) 
and prostate cancer samples at various stages of disease (28 prostatic intraepithelial 
neoplasia (PIN) lesions, 62 hormone-sensitive and 31 castrate-resistant tumors). This 
study showed IKK expression to be upregulated in malignant prostate cancer samples as 
compared to normal tissue, with the highest IKK expression found in the castrate-
resistant tumor samples [106]. In ovarian cancer, a study showed that IKK is 
overexpressed in 63 of 95 ovarian cancer samples and that high levels of IKK were 
associated with poor disease prognosis in these samples [107]. In glioma, high IKK was 
found in 38 out of 71 paraffin-embedded glioma samples [108]. This study also showed 
that IKK conveyed resistance to apoptotis to glioma cells that were tranduced with IKK 
expression, implicating an oncogenic role for IKK in the context of glioma [108]. In 
clear cell renal cell carcinoma, expression profiling of 93 tumor samples revealed that 
high IKK expression levels was correlated with a 5.3fold increase in patient mortality 
[109]. In pancreatic ductal adenocarcinoma, high IKK expression was observed in 50 
out of 78 tumor samples [110]. Finally, in non-small cell lung cancer, IKK expression 
was shown to be induced by STAT3 activation in the context of tobacco and nicotine 
exposure [111]. All of these studies taken together implicate IKK as not only an 
important player in breast cancer, but possibly a useful prognostic tool in other cancers as 
well. 
 
TBK1 IN CANCER 
TBK1 was identified to be highly expressed in lung, breast and colon cancers. In 
addition, a TBK1 mutation, P675L was identified in lung adenocarcinoma [112-114]. 
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TBK1 and IRF3 were identified to promote angiogenesis through a high throughput gain 
of function screen. HEK293T cells were transfected with a comprehensive genome-
encompassing cDNA library, the conditioned media from these transfected cells was 
collected and fed to human umbilical vein endothelial cells (HUVECs) to determine 
which genes could trigger the production of proangiogenic secreted factors [112]. TBK1, 
TRIF, and IRF3 all scored positively in this screen as triggers. Further analysis revealed 
that TBK1 stimulated the production of several different secreted factors including the 
endothelial growth factors RANTES, IL-8. This pro-angiogenic fuction of TBK1 
expression began to link TBK1 as a possible player in cancer progression [112]. 
A later study mechanistically linked TBK1 to tumorigenesis by showing its 
association with RalB [76]. RalB is a monomeric RalGTPase, a part of the RasGTPase 
superfamily, that has been implicated as an essential component of Ras-induced 
oncogenic transformation. RalB is required to suppress the apoptotic checkpoint 
activation. RalB recruits the binding of the exocyst complex, a large super complex 
composed of eight core secretory proteins. One of these proteins, Sec5, was shown to be 
essential for RalB mediated apoptotic control. In a study to understand the mechanism of 
RalB/Sec5 action, Chien et al. identified TBK1 to be actively recruited to the RalB/Sec5 
complex. Furthermore, depletion of TBK1 protein by siRNA mimicked the effects of 
RalB and Sec5 depletion, resulting in TBK1 deficient cells undergoing an asynchronous 
apoptotic program. Importantly, TBK1 deficient MEFs were unable to undergo Ras-
induced oncogenic transformation as compared to their wildtype counterparts. Instead, 
transduction of TBK1 deficient MEFs with oncogenic K-RasG12V resulted in apoptosis 
[76]. 
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TBK1 has also been implicated in RAS signaling as a protein whose suppression 
resulted in synthetic lethality in oncogenic KRAS-dependent lung cancer cell lines [114]. 
Barbie et al. found that cell lines that are dependent on mutant KRAS expression are also 
dependent on TBK1. Expression profile analyses were performed on patient-derived 
tumors from 128 lung adenocarcinomas. Of 19 mutant KRAS tumors, 14 showed an 
enrichment in the NF-B activation signature. Expression of the NF-B super repressor 
induced the selective apoptosis of KRAS mutant cell lines. These data provides evidence 
that TBK1 and NF-B activation is a co-dependency for KRAS-dependent lung cancers 
[114]. 
Recent work by two independent groups has identified AKT as a downstream 
phosphorylation target of both IKK and TBK1 in the context of cancer [115, 116]. Since 
IKK was originally identified as a breast cancer oncogene by replacing AKT in a gain-
of-function screen [72], it would follow that AKT is likely a downstream target of IKK 
signaling. Overexpression of wildtype but not kinase-dead IKK or TBK1 resulted in an 
increase in AKT phosphorylation at Ser473 and Thr308 as well an increase in 
phosphorylation of the AKT substrates FoxO1, TSC2, p70S6K and GSK-3. IKK and 
TBK1 were capable of phosphorylating AKT in vitro in a dose-dependent manner. Both 
groups also showed that IKK/TBK1-mediated phosphorylation of AKT was independent 
of mTORC2. However, whether AKT phosphorylation is dependent on PI3K signaling 
remains controversial. One group showed that the treatment IKK-expressing Ikbke-/- 
MEFs by the PI3K inhibitors LY294002 and Wortmanin did not affect IKK-induced 
AKT phosphorylation [107]. On the other hand, the other group performed a similar 
experiment and showed that LY294002 and Wortmanin treatment significantly decreased 
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the ability of IKK to phosphorylate AKT [116].  Thus, the overlap of IKK and PI3K 
signaling remains unclear. 
 
ELUCIDATING THE REGULATION AND EFFECTORS OF IKK 
IN CANCER 
 Although the mechanism of IKK signaling in the context of innate immunity and 
proinflammatory NF-B signaling has been studied, the pathway and regulation of IKK 
signaling in the context cancer remains relatively unknown. 
 Both degradation-dependent K48-linked and degradation-independent K63- and 
Met1-linked ubiquitination have been shown to play a critical role in the regulation of 
various members of the canonical NF-κB pathway [13]. In my dissertation work, I 
explored the regulation of IKK by ubiquitination and determined that IKK undergoes 
K63-linked degradation-independent ubiquitination in the context of breast cancer 
(Chapter 2).  
IKK has been shown to have several substrates in the context of innate immunity 
and NF-κB activation. However, the downstream effectors of IKK signaling in the 
context of breast cancer have not been well-studied. In collaborative work with Rhine 
Shen and the Cantley lab, we undertook an unbiased positional peptide screen in order to 
identify novel IKK kinase targets. Through this approach, we identified and 
characterized two novel and important substrates for IKK phosphorylation in the context 
of breast cancer, CYLD (Chapter 3) and TRAF2 (Chapter 4). 
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Taken together, the work presented in this dissertation has elucidated an entirely 
novel oncogenic signaling network of IKK-mediated cell transformation in cancer.
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The IB kinase  (IKK, IKBKE) is a breast cancer oncogene that is amplified in 
~30% of breast cancers and that promotes malignant transformation through the 
activation of NF-B signaling. Here, we show that IKK are modified and regulated 
by K63-linked polyubiquitination at Lysine 30 and Lysine 401. We found that IKK 
K63-linked polyubiquitination is essential for IKK kinase activity, IKK-mediated 
NF-B activation and IKK-induced malignant transformation. TRAF2 serves as the 
K63 ubiquitin E3 ligase that binds to and modifies IKK.  Together, these 
observations demonstrate that IKK is regulated by K63-linked ubiquitination in the 




Nuclear factor B (NF-B) signaling plays a critical role in inflammation and 
innate immunity. Chronic inflammation has long been implicated in the pathogenesis 
of both solid tumors and blood malignancies [1-3] where aberrant NF-B signaling in 
the tumor microenvironment plays an important role [4, 5]. In addition, several 
studies have also shown that the dysregulation of specific NF-B family members can 
contribute to cell transformation in a cell autonomous manner. For example, deletion 
of the tumor suppressor, CYLD, leads to the development of familial cylindromatosis 
[6-9]. Mutations in the NF-B effector genes NFKB1 and NFKB2 play a role in 
multiple myeloma [10] and mutations both negative (A20) and positive (CARD11, 
TRAF2, TRAF5, TAK1 and RANK) regulators of NF-B have been characterized in B-
cell lymphoma [11]. More recently, several NF-B pathway members including 
IKBKB, IKBKG, TRAF6, and RIP1 have been found to be located in regions of 
recurrent amplification in epithelial cancers [12].  
 The canonical NF-B pathway is activated in response to various 
proinflammatory signals and converges upon the activation of the IB kinase (IKK) 
complex by members of the TRAF E3 ligase family of proteins [2]. The IKK 
complex consists of two catalytic subunits, IKK and IKK, and the regulatory 
subunit IKK/NEMO [13, 14]. Multiple types of proteasome-dependent and -
independent forms of ubiquitination are required for the activation of the NF-B 
signaling cascade [15-17]. Several studies demonstrated that the proteasome-
independent Lysine63 (K63)-linked ubiquitination of IKK is a key step in the 
activation of the IKK complex [18, 19]. More recent studies have also shown that 
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linear (Met1) ubiquitination of IKK is also sufficient for IKK complex activation 
[20-22]. The activation of the IKK complex by non-degradative ubiquitination leads 
to the phosphorylation of the inhibitor of B (IB) proteins [23]. This 
phosphorylation event triggers the Lysine48 (K48)-linked ubiquitination and 
subsequent preoteasome-mediated degradation of the IB proteins, which in turn 
allows for the nuclear translocation of the NF-B dimers and activation of 
proimflammatory NF-B response genes [17]. 
Inhibitor of B kinase  (IKK, IKBKE) is a non-canonical IKK protein that 
activates interferon, NF-B and STAT signaling. Together with its binding partner 
TBK1, IKK regulates the interferon response pathway to viral challenge by 
phosphorylation of IRF3 and IRF7 [24-26]. This phosphorylation results in 
translocation of IRF3 and IRF7 into the nucleus and subsequent activation type I 
interferon genes [24]. IKK has also been shown to be a breast cancer oncogene that 
is amplified and overexpressed in ~30% of breast cancers. Overexpression of IKBKE 
induced malignant transformation of normal epithelial cells in an NF-B-dependent 
manner and suppression of IKK in breast cancer cells that harbor amplifications 
involving IKBKE induced cell death [27]. We have identified the familial tumor 
suppressor and deubiquitinase CYLD as a direct substrate of IKK phosphorylation 
and effector of IKK-mediated transformation [28]. However, the mechanism(s) that 
regulate IKK remain poorly understood. 
Here we found that IKK is K63-ubiquitinated and investigate the role of this 
modification in IKK-mediated NF-B activation and cell transformation. 
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MATERIALS AND METHODS 
Antibodies, Plasmids, and Reagents 
The antibodies used include: Myc (clone 4A6) (Millipore), cIAP1, K48-linkage 
specific Ubiquitin, K63-linkage specific Ubiquitin, phospho-CYLD, TRAF2 (Rabbit) 
and TANK (Cell Signaling Technologies), V5-HRP (Invitrogen), Ubiquitin (FL-76 
and PD-1),  actin-HRP, CYLD, TRAF2 (Mouse) (Santa Cruz Biotechnology), IKK 
and (Sigma-Aldrich), HA (Clone12C5) (Boehringer Mannheim). The IKK phospho-
substrate antibody was previously described [28]. Anti-M2 Flag affinity gel sepharose 
was obtained from Sigma-Aldrich and Glutathione affinity gel sepharose was 
obtained from GE Healthcare. 
pBp Flag-IKK and Myr-Flag-IKK were used as described [27]. GST-IKK and 
Myc-CYLD was used as described [28]. MF-IKK K30A, MF-IKK K401A, MF-
IKK K416A, MF-IKK K30R, MF-IKK K401R, MF-IKK K416R, V5-TBK1 
K30R, V5-TBK1 K401R were created using the QuickChange site-directed 
mutagenesis protocol (Stratagene). V5-TRAF2, V5-TRAF2 RING, V5-IKK, V5-
IKK K30R, V5-IKK K401R, V5-IKK K416R, V5-TBK1, Myc-IKK, Myc-IKK 
K30R, Myc-IKK K401R, Myc-IKK K416R were generated by Gateway cloning 
into the pLEX-V5-Blast lentiviral vector. FLAG-TRAF6 and FLAG-TRAF6 C70A 
were obtained as a gift from Dr. Hui-Kuan Lin (M.D. Anderson). HA-ubiquitin, HA-
Ub K63-only, and HA-Ub K48-only were used as described previously [27, 29]. 




Cell Culture, Transfection, Immunoprecipitation, and Immunoblotting. 
HEK293T, MCF-7 cells were obtained from the American Type Culture Collection 
(ATCC) and were propagated in DMEM containing 10% FBS. ZR-75-1 cells were 
obtained from ATCC and propagated in RPMI1640 containing 10% FBS. HA1EM 
and HMLEM cells have been described [27]. Transfection experiments were 
performed using Fugene (Roche). U2OS shUb-Ub(WT) and U2OS shUb-Ub(K63R) 
cells were cultured as previously described [30]. Immunoprecipitations using in 
U2OS cell lysates were performed as previously described [30]. All other 
immunoprecipitations and immunoblots were performed as described [28]. 
Densitometry was assessed using by ImageJ software. 
 
Mass Spectrometry Analysis HEK293T cells were cotransfected with GST-IKK 
and HA-Ub. GST immune complexes were isolated using Glutathione Sepharose (GE 
Healthcare) and the sample was resolved on SDS-PAGE and visualized with 
Colloidal Blue (Invitrogen). Four bands were excised and subjected to in-gel trypsin 
digestion. The tryptic peptides were extracted from the gel and analyzed by liquid 
chromatography MS/MS. Peptides were separated across a 50-min gradient ranging 
from 7 to 30% (v/v) acetonitrile in 0.1% (v/v) trifluoroacetic acid in a microcapillary 
(125 μm × 18 cm) column packed with C18 reverse-phase material (Magic C18AQ, 5-
μm particles, 200-Å pore size, Michrom Bioresources) and analyzed on-line on a 
hybrid linear ion trap-Orbitrap mass spectrometer (LTQ-Orbitrap, Thermo-Electron). 
For each cycle, one full MS scan acquired on the Orbitrap at high mass resolution was 
followed by 10 MS/MS spectra on the linear ion trap from the 10 most abundant ions. 
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MS/MS spectra were searched using the Sequest algorithm against the human IPI 
protein database. Dynamic modifications of 114.0429275 Da on lysine was allowed 
for ubiquitination. All peptide matches were initially filtered based on enzyme 
specificity, mass measurement error, Xcorr and dCorr scores and further manually 
validated for peptide identification and site localization. 
 
NF-B reporter assays 
GloResponse NF-κB-RE-luc2P HEK293T cells (Promega) were transfected with V5-
IKK WT, V5-IKK K30R and V5-IKK K401R. NF-B activity was measured 36h 
post-transfection according to the protocol for the One-Glo Luciferase assay 
(Promega). Luciferase values are reported directly in raw light units (RLU). 
 
Tumorigenicity assay 
2 x 106 cells were subcutaneously implanted into immunodeficient mice (Balb/c 
Nude, Charles River Laboratories) anesthetized with isofluorane. Two mice were 
used per group, and three implantation sites were made per mouse. Tumors were 
measured at 21 d after implantation. 
 
In vitro cell transformation assay 
Growth of HA1EM cells in soft agar was determined by plating 5 X 104 cells in 
triplicate in 0.4% Noble agar. Colonies greater than 100m in diameter were counted 
28 d after plating. 
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RESULTS 
Ubiquitination of IKK 
Since other members of the IKK family are known to be modified and 
regulated by ubiquitination [15], we tested whether IKK is ubiquitinated by 
introducing hemagluttinin (HA)-tagged ubiquitin (HA-Ub) and either Flag-tagged or 
myristolated-Flag-tagged IKK (F-IKK or MF-IKK) into HEK293T cells. We 
purified HA immune complexes and found ubiquitinated IKK species (Figure 2.1A).  
To determine whether IKK ubiquitination occurs under physiological 
conditions, we investigated IKK ubiquitination under conditions where IKK 
expression induced cell transformation. We previously showed that expression of 
IKK confers tumorigenicity to human embryonic kidney (HEK) epithelial and 
human mammary epithelial cells (HMEC) expressing the SV40 early region 
(SV40ER), the catalytic subunit of telomerase (hTERT) and a constitutively active 
form of MEK (MEKDD) (Boehm et al., 2007). We isolated IKK immune complexes 
from transformed HEK (HA1EM F-IKK) and HMEC (HMLEM MF-IKK) cells 
and found that IKK is polyubiquitinated in both cell types (Figure. 2.1B and C 
respectively). We then examined whether IKK is ubiquitinated in breast cancer cell 
lines that harbor IKBKE amplification and are dependent on IKK [27]. Specifically, 
we assessed the status of IKK ubiquitination in MCF-7 and ZR-75-1 cells and found 
endogenous polyubiquitinated species of IKK in both cell lines (Figure 2.1D and E). 
Together these observations demonstrate that ubiquitination of IKK occurs in the 

































Figure 2.1. IKK is ubiquitinated in the context of cell transformation 
(A) IKK is ubiquitinated in HEK293T cells. HA immune complexes were isolated 
from HEK293T cells expressing the indicated proteins and analyzed by immunoblot 
with an antibody specific for IKK. (B and C) IKK is ubiquitinated in transformed 
cells. IKK immune complexes were isolated from HA1EM MF-IKK (B) or 
HMLEM MF-IKK (C) cells using an IKK-specific antibody and analyzed by 
immunoblot by the same IKK antibody. 5% of the whole cell lysate was loaded as an 
input control. Rabbit immunoglobulin (rIgG) was used as a control. (D and E) IKK 
is ubiquitinated in breast cancer cell lines. Endogenous IKK immune complexes 
were isolated from MCF-7(D) and ZR-75-1(E) breast cancer cell lines using an IKK-
specific antibody and analyzed by immunoblot by the same IKK antibody. 5% of the 
whole cell lysate was loaded as an input control.  
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IKK undergoes K63-linkage-specific ubiquitination 
Whereas Lysine48 (K48)-linked polyubiquitin chains target ubiquitinated 
substrates to the proteasome for protein degradation, several forms of proteasome- 
and degradation- independent polyubiquitin chains exist including Lysine63 (K63)-
linked, Lysine11 (K11)-linked and linear (Met1) ubiquitin chains [31]. To assess 
whether IKK ubiquitination is proteasome-dependent, we treated transformed 
HA1EM MF-IKK cells and MCF-7 and ZR-75-1 breast cancer cells with a 
combination of two proteasome inhibitors, MG-132 and Velcade. As expected, the 
overall level of ubiquitination was increased in the presence of proteasome inhibitors. 
However, under these conditions, we failed to observe differences in the level of 
IKK protein, suggesting that IKK ubiquitination does not regulate IKK stability 
(Figure 2.2A).  
To determine whether IKK was modified by K48- or K63-linked 
ubiquitination, we used three methods to determine the type of nature of ubiquitin 
modification to IKK. First, we introduced Myc-tagged IKK along with HA-tagged 
wildtype, K48-only, or K63-only ubiquitin mutants into HEK293T cells. These 
mutant HA-ubiquitin constructs can only form either K48-likage-specific (K48-only) 
or K63-linkage-specific (K63-only) polyubiquitin chains, respectively. We isolated 
IKK immune complexes and found that IKK undergoes robust ubiquitination by 
wildtype and K63-only ubiquitin (Figure 2.2B). In contrast, we failed to find evidence 




Figure 2.2. IKK is modified by K63-linked ubiquitination 
(A) Proteasome inhibitor treatment does not affect IKK protein levels. MCF-7 and 
ZR-75-1 breast cancer cells and HA1EM MF-IKK transformed cells were subject to 
treatment with a cocktail of proteasome inhibitors (10M MG-132, 1M Velcade) for 
4h. Immunoblotting was performed with the indicated antibodies. (B) IKK 
undergoes Lys63-linked ubiquitination in HEK293T cells. HEK293T cells were 
cotransfected as indicated with HA-tagged K63-only or K48-only ubiquitin mutants. 
Myc immune complexes were isolated followed by immunoblotting with the 






Figure 2.2 Continued 
(C) IKK undergoes Lys63-linked ubiquitination in breast cancer cell lines. 
Endogenous Lys48-linked (K48) polyubiquitin and Lys63-linked (K63) polyubiquitin 
immune complexes were isolated followed by immunoblotting with the indicated 
antibodies in MCF-7 and ZR-75-1 breast cancer cell lines. rIgG was used as a control. 
(D) U2OS-shUb-Ub(WT) or U2OS-shUb-Ub(K63R) cells were treated with 
tetracycline (TET) (1 g/ml) for 4d. IKK immune complexes were isolated followed 
by immunoblot analysis with the indicated antibodies. 5% of the whole cell lysate 
was loaded for comparison (input). 
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To confirm these observations, we used linkage-specific ubiquitin antibodies. 
In MCF-7 and ZR-75-1 breast cancer cells, we isolated immune complexes using 
either a K48- or K63- linkage-specific ubiquitin antibody and found that IKK was 
present only in the immune complexes formed by the K63-linkage-specific antibody 
(Figure 2.2C). 
Finally, we used a genetic system in which endogenous forms of ubiquitin are 
inducibly suppressed by the expression of ubiquitin-specific shRNAs at the same time 
that wild type or mutant ubiquitin are inducibly expressed in U2OS cells [30]. In the 
U2OS shUb-Ub(WT) cells, the exogenous construct expresses an shRNA-insensitive 
wildtype ubiquitin. In the U2OS shUb-Ub(K63R) cells, the exogenous construct 
expressed an shRNA-insensitive K63R mutant form of ubiquitin – this mutant 
harbors a lysine-to-arginine mutation at the K63 residue, rendering this ubiquitin 
incapable of forming K63-linkage-specific chains. Using this system, we isolated 
IKK immune complexes from U2OS shUb-Ub(WT) and shUb-Ub(K63R) cells with 
and without tetracycline treatment and then assessed these complexes for the presence 
of ubiquitin. We confirmed that IKKε is capable of undergoing modification by the 
WT ubiquitin chains but is no longer able to be modified by the K63R chains (Figure 
2.2D). Taken together, we concluded that IKK is modified by K63-linked ubiquitin 
chains in the context of breast cancer cells. 
 
IKK is ubiquitinated at K30, K401 and K416 
To determine the lysine residues on which IKK is ubiquitinated, we 
expressed GST-tagged IKKε and HA-tagged ubiquitin in HEK293T cells, isolated 
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GST immune complexes and performed mass spectrometry. Specifically, we 
separated GST immune complexes by electrophoresis and submitted four bands for  
mass spectrometry analysis (Figure 2.3A). We obtained 58.2% coverage of the IKKε 
protein and 64.7% (22 out of 34) coverage of the internal lysines. From this analysis, 
three lysine residues of IKK were identified as ubiquitinated: K30, K401, and K416 
(Figure 2.3B, Table 2.1). 
To confirm these observations, we generated site-specific lysine-to-alanine 
(K30A, K401A, K416A) and lysine-to-arginine (K30R, K401R, K416R) IKKε 
mutants and assessed whether each of these mutants are modified by ubiquitination. 
We introduced wildtype and mutant IKK along with HA-ubiquitin into HEK293T 
cells, isolated IKK immune complexes and assessed for IKK ubiquitination. We 
found that the K30 and K401 mutants exhibited decreased IKK ubiquitination, but 
could not detect changes in ubiquitinated species of IKK K416 mutant (Figure 
2.4A). We noted that the lysine-to-arginine and lysine-to-alanine mutants behaved 
identically in all assays. 
We then created stable lines expressing each IKK mutant (Figure 2.4B) and 
determined whether these mutants exhibited differential expression of ubiquitinated 
IKK species. We found that the K30 and K401 mutant forms of IKK showed a 
significant decrease in higher molecular weight ubiquitinated species of IKK while 
the K416 mutant showed no signification change (Figure 2.4C). These observations 




Figure 2.3. Identification of IKK ubiquitination residues. 
(A)Ubiquitinated IKK analysis by mass spectrometry. GST-IKK was cotransfected 
into HEK293T cells with HA-Ub. GST immune complexes were isolated and 
subjected to SDS-PAGE followed by Colloidal Blue staining. The band 
corresponding to IKK (arrow) and 3 additional higher molecular weight bands 
(arrowheads) were excised from the gel and digested with trypsin and chymotrypsin. 
Ubiquitination sites were mapped by microcapillary LC/MS/MS. (B) Amino acid 
sequence of IKK. Mass spectrometry analysis covered 58.2% of the IKK amino 
acid sequence (underlined) and 64.7% (22/34) of the internal lysines (bold). Three 












































Table 2.1. Mass spectrometry analysis of ubiquitinated IKK. All the IKK peptides 
that were identified in the mass spectrometry analysis are listed in increasing 
positional order and corresponding molecular mass and peptide sequence. Peptides 






Figure 2.4. IKK is ubiquitinated on K30, K401 and K416. 
(A) IKK ubiquitination site mutants in HEK293T cells. Site-directed MF-IKK 
mutants were created in which K30, K401 and K416 residues were changed to an 
alanine. These mutants were cotransfected into HEK293T cells with HA-Ub. IKK 
immune complexes were isolated with an IKK-specific antibody and analyzed by 
immunoblotting. (B) IKK ubiquitination site mutants in transformed HA1EM cells. 
Site-directed MF-IKK mutants were created in which K30, K401 and K416 residues 
were changed to an arginine. These mutants were retrovirally introduced into 
HA1EM cells. (C) Mutant IKK ubiquitination status in transformed HA1EM cells. 
IKK immune complexes were isolated from HA1EM cells expressing wildtype, 
K30A, K401A and K416A MF-IKK with Anti-M2 Flag Sepharose and analyzed by 
immunoblotting. 
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IKK ubiquitination at K30 and K401 are essential for IKK kinase activity 
We previously identified the deubiquitinase CYLD as a downstream kinase 
target of IKK [28]. To determine the importance of IKK K63-linked ubiquitination 
on IKK kinase function, we used our genetic ubiquitin replacement system. We 
isolated CYLD immune complexes from U2OS shUb-Ub(WT) and shUb-Ub(K63R) 
cells with and without tetracycline treatment and determined the levels of both 
phospho (pCYLD) - and total CYLD protein. We found that in the conditions under 
which IKK cannot be K63-linked ubiquitinated, IKK also exhibited impaired 
kinase activity (Figure 2.5A). Specifically, we found that under conditions in which 
IKK was not ubiquitinated, we failed to detect phosphorylation of CYLD as assessed 
by a phosphospecific antibody directed to pCYLD and alterations in CYLD mobility.  
To determine the effect of the K30R and K401R mutants on IKK kinase 
activity, we assessed the ability of wildtype and mutant IKK to phosphorylate 
CYLD in vivo. We transiently cotransfected HEK293T cells with Myc-tagged CYLD 
and either WT, K30R, or K401R IKK. We isolated Myc immune complexes and 
determined CYLD phosphorylation status by IKK pSubstrate immunoblot. These 
observations confirmed that although wildtype IKK phosphorylates CYLD, neither 
of the mutant forms of IKK exhibited kinase activity (Figure 2.5B). We note that we 
found both IKK mutants in CYLD immune complexes, indicating that despite 
lacking enzymatic activity, these mutants retained the ability to form a complex with 
CYLD. 
IKK activates the NF-B pathway through a non-conventional mechanism 
[32], and this activity is essential for IKK-mediated transformation [27]. To assess  
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Figure 2.5. IKK K63-linked ubiquitination at K30 and K401 is essential for 
IKK function 
(A) IKK kinase function is dependent on its K63-linked ubiquitination. U2OS-shUb-
Ub(WT) or U2OS-shUb-Ub(K63R) cells were treated with tetracycline (TET) (1 
g/ml). CYLD immune complexes were isolated followed by immunoblot analysis 
with antibodies for phospho-CYLD and total CYLD. rIgG was used for control 
immunoprecipitations. (B) Effects of IKK ubiquitination mutants on CYLD 
phosphorylation. HEK293T cells were transfected as indicated. Myc-CYLD immune 
complexes were isolated and analyzed with antibodies specific for CYLD, IKK, and 
IKK phospho-substrates. (C) Effects of IKK ubiquitination mutants on NF-B 
activation. GloResponse NF-κB-RE-luc2P HEK293T cells were transfected with V5-
IKK WT, V5-IKK K30R and V5-IKK K401R and analyzed by the One-Glo 
Luciferase assay. Raw light unit (RLU) activities are reported. Results reported as 
mean ± SD of six experiments. *p = 1.1 x 10-7, calculated by a standard t test. 
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the effects of disrupting IKK ubiquitination on NF-B activation, we examined 
whether the IKK mutants exhibited activity in a NF-κB luciferase reporter assay 
(Figure 2.5C). Consistent with the kinase activity data, these results indicated that 
WT but not K30R or K401R mutant IKK was able to induce the NF-B luciferase 
reporter activity. 
 
IKK ubiquitination at K30 and K401 are essential for IKK-mediated 
transformation 
To interrogate the role of ubiquitination in IKK-mediated cell transformation, 
we assessed whether mutant forms of IKK were able to transform human cells 
(Figure 2.6A). In HA1EM cells, expression of wild type IKK induces robust 
anchorage independent colony growth. In contrast, when we expressed the K30 and 
K401 IKK mutants, we found that these mutants were markedly defective in their 
ability to induce anchorage independent colony growth. This transformation 
phenotype was identical in both the lysine-to-arginine and lysine-to-alanine mutants 
(Figure 2.6B). 
To confirm these in vitro findings, we then assessed whether expression of 
WT or mutant IKK conferred tumorigenicity. We found that WT IKK induced 
tumor formation at 50% incidence, which is consistent with previous published data 
[27]. In contrast expression of the K30 and K401 IKK mutants exhibited an impaired 


















Figure 2.6. IKK ubiquitination at K30 and K401 is essential for IKK-mediated 
transformation 
(A) Anchorage-independent growth of HA1EM cells transformed with wildtype and 
mutant IKK. Colony formation of cells from was analyzed after 28 d. Results 
reported as mean ± SD of three experiments. *p = 0.0045, calculated by a standard t 
test. (B) Anchorage-independent growth of HA1EM cells transformed with wildtype 
and mutant lysine-to-alanine IKK. Colony formation of cells from was analyzed 
after 28 d. Results reported as mean ± SD of three experiments. * p = 3.9 x 10-7, 
calculated by a standard t test. (C) Tumorigenicity of HA1EM MF-IKK wildtype 
and mutant cells. HA1EM cells expressing wildtype or mutant IKK were introduced 
subcutaneously into immunodeficient mice. Tumor formation shown as a percentage 
assessed at 21 days postinjection.  
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linkage-specific ubiquitination of IKK at K30 and K401 are essential for the ability 
of IKK to mediate malignant cell transformation. 
 
TRAF2 associates with and ubiquitinates IKK 
Having defined a role for K63-linked ubiquitination in the regulation of IKK 
in both the context of NF-B activation and cell transformation, we sought to identify 
the E3 ligase responsible for IKK ubiquitination. IKK forms a complex that 
includes TBK1, TRAF2, cIAP-1 and TANK in the context of innate responses to viral 
challenge [33, 34]. TRAF2 has been shown to be the E3 ligase that promotes the 
K63-linked ubiquitination of RIP1 during activation of the canonical TNF receptor-
induced NF-B pathway [35-37]. Based on these observations, we tested whether 
TRAF2 serves as an E3 ligase complex to modify IKK. 
To confirm that IKK interacts with TRAF2, we isolated IKK immune 
complexes in the MCF-7 and ZR-75-1 breast cancer cell lines. In both cell lines, we 
confirmed that IKK binds to TRAF2 in transformed cells (Figure 2.7A). To 
determine if TRAF2 catalyzes IKK ubiquitination, we introduced IKK and either a 
wildtype or an E3 ligase-deficient mutant TRAF2 (TRAF2 RING) into HEK293T 
cells. The TRAF2 RING construct harbors an 87 amino acid N-terminal deletion of 
the conserved RING domain, which inactivates its E3 ligase activity [37]. In these 
cells, we assessed whether IKK was ubiquitinated in the presence of TRAF2 and 




Figure 2.7. TRAF2 is a K63-linked ubiquitin ligase that modifies IKK 
(A) IKK binds to TRAF2 in breast cancer cell lines. Endogenous IKK immune 
complexes were isolated from MCF-7 and ZR-75-1 breast cancer cell lines using an 
IKK-specific antibody and analyzed by immunoblotting. rIgG was used as a control. 
(B) TRAF2 ubiquitinates IKK. HEK293T cells were transfected as indicated. 
Lysates were analyzed by immunoblot with antibodies for IKK, -actin and TRAF2. 
(C) TRAF6 does not ubiquitinate IKK. HEK293T cells were transfected as 
indicated. Lysates were analyzed by immunoblot with antibodies for IKK, -actin 
TRAF6 
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contrast, we failed to find polyubiquitinated forms of IKK in cells co-expressing 
IKK and the TRAF2 RING mutant (Figure 2.7B).  
To confirm the specificity of TRAF2 for IKK, we tested whether expression 
of a different TRAF family member, TRAF6, which has been shown to catalyze the 
K63-linked polyubuiqitination of Akt [38], induced IKK ubiquitination. We found 
that neither wildtype nor catalytically inactive (C70A) TRAF6 was capable of 
catalyzing IKK ubiquitination (Figure 2.7C). These observations provided evidence 
that TRAF2, but not TRAF6, catalyzed IKK polyubiquitination and that the RING 
domain of TRAF2 is required for this activity. 
To determine whether TRAF2 is required for IKK ubiquitination, we 
suppressed TRAF2 expression using two independent TRAF2-specific shRNAs 
(shTRAF2 #1 and shTRAF2 #2) in MCF-7 and ZR-75-1 breast cancer cells. These 
TRAF2-specific shRNAs suppressed the levels of TRAF2 expression in both MCF-7 
and ZR-75-1 cells (Figure 2.8A and 2.8B respectively). We then isolated IKK 
immune complexes from these cells and found that both MCF-7 and ZR-75-1 cells in 
which TRAF2 was suppressed exhibited a decreased level of polyubiquitinated IKK 
(Figure 2.8C and 2.8D respectively). We next used the K63-linkage specific antibody 
to isolate immune complexes and found that in cells with suppressed TRAF2 had 
decreased amounts of K63-ubiquitin modified IKK in both MCF-7 and ZR-75-1 
breast cancer cells (Figure 2.8E and 2.8F respectively). These observations provide 
evidence that TRAF2 is a K63-linkage E3 ubiquitin ligase enzyme that associates 
with IKK. 
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 Figure 2.8. TRAF2 suppression reduces IKK K63-linked ubiquitination 
(A and B) Effects of TRAF2 suppression in MCF-7(A) and ZR-75-1(B) cells. MCF-7 
and ZR-75-1 cells were transduced with shTRAF2#1, shTRAF2#2 or control 
shLACZ. Lysates were analyzed by immunoblot with antibodies for IKK, TRAF2 
and -actin. Relative TRAF2 levels were calculated by densitometry analysis. (C and 
D) IKK immune complexes were isolated from MCF-7(C) and ZR-75-1(D) cells 
with TRAF2 suppression with an IKK-specific antibody and analyzed by 
immunoblot with an IKK antibody. rIgG was used for control immunoprecipitations. 
(E and F) K63-linkage ubiquitin immune complexes were isolated from MCF-7(E) 
and ZR-75-1(F) cells with TRAF2 suppression with an K63-linkage-specific ubiquitin 
antibody and analyzed by immunoblot with an IKK antibody. rIgG was used for 
control immunoprecipitations. Relative IKK levels were calculated by densitometry 
analysis. 
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TBK1 undergoes K63-linked ubiquitination at K30 and K401 
 IKK shares 65% similarity to another non-canonical IKK protein, TANK-
binding kinase 1 (TBK1) [39]. In the context of innate immunity, IKK and TBK1 
work in complex to activate the interferon response. Given the structural and 
functional similarity between these two kinases, we next explored whether TBK1 is 
also regulated by K63-linked ubiquitination. 
 To determine if TBK1 undergoes K63-linked ubiquitination, we introduced 
GST-tagged TBK1 along with HA-tagged wildtype or K63-only ubiquitin mutants 
into HEK293T cells. We isolated GST immune complexes and found that TBK1 
undergoes robust ubiquitination by wildtype and K63-only ubiquitin (Figure 2.9A). 
Interestingly, the K30 and K401 are conserved between the IKK and TBK1 protein 
sequence. Since our previous results indicated that IKK was ubiquitinated at these 
two residues, we next interrogated whether TBK1 was also ubiquitinated at these 
residues. We generated site-specific lysine-to-arginine (K30R, K401R) TBK1 
mutants and assessed whether each of these mutants is capable of undergoing K63-
linked ubiquitination. We introduced wildtype and mutant V5-tagged TBK1 along 
with K63-only HA-ubiquitin into HEK293T cells. We isolated V5 immune 
complexes and assessed TBK1 ubiquitination. We found that, similar to IKK, the 
K30 and K401 TBK1 mutants exhibited a decrease in ubiquitination (Figure 2.9B). 
Taken together, this data is evidence that TBK1 is also regulated by K63-linked 





















Figure 2.9. TBK1 undergoes K63-linked ubiquitination 
(A) HEK293T cells were cotransfected as indicated with HA-tagged wildtype or 
K63-only ubiquitin. GST immune complexes were isolated followed by 
immunoblotting with the indicated antibodies. (B) TBK1 ubiquitination site mutants 
in HEK293T cells. Site-directed V5-TBK1 mutants were created in which K30 and 
K401 residues were changed to an arginine. These mutants were cotransfected into 
HEK293T cells with HA-Ub K63 only. V5 immune complexes were isolated with 
and analyzed by immunoblotting with indicated antibodies.  
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DISCUSSION 
K63-linked ubiquitination of IKK is essential for its activity as an oncogene 
In the context of innate immunity, IKK plays a key regulatory role in 
initiating the interferon response to viral challenge. In addition, IKK has been 
identified as a breast cancer oncogene that is amplified and overexpressed in ~30% of 
breast cancers. Breast cancer cell lines that harbor amplifications involving IKBKE 
are dependent on IKK expression for survival. Thus, understanding the mechanism 
of IKK regulation and function is an important key step towards elucidating its roles 
not only in these biological processes but also in the context of malignant disease. 
Here, we have used a combination of biochemical assays and an experimental 
model system of defined genetic composition to demonstrate that IKK is specifically 
modified by K63-linked ubiquitination. Through a large-scale mass spectrometry 
approach, we have identified IKK residues that are modified by ubiquitination. 
Using mutational analysis, we have determined that K30 and K401 are important sites 
of IKK modification and that the ubiquitination of IKK on these two sites is 
essential for its ability to act both as an NF-B activator and as a breast cancer 
oncogene.  
In prior work, we showed that IKK induces cell transformation in a manner 
that is dependent upon activation of the NF-B pathway. Here we show that K63-
linked ubiquitination of IKK is required for IKK kinase activity, suggesting that 
this modification induces either an allosteric or complex formation change to regulate 
kinase activity. Since IKK also regulates interferon, STAT and NF-B signaling in 
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the context of viral challenge or other pro-inflammatory stimuli [40], further studies 
are necessary to dissect the role of K63-linked ubiquitination in these settings. 
We found that ubiquitination of both K30 or K401 are required for kinase 
activity. Since these mutants exhibit equivalent binding to CYLD, it is unlikely that 
these mutants disrupt the overall structure of IKK. Here, we have also shown that the 
analogous residues in TBK1 that we identified as ubiquitinated in IKK are also 
ubiquitinated in TBK1. Work in the Eck lab has described the structure of TBK1 
(unpublished). Upon mapping of the residues K30 and K401 onto the TBK1 crystal 
structure, we found that these residues reside on opposing faces of the protein 
structure but are in close approximation when TBK1 forms a homodimer (Figure 
2.10). This suggests that these residues may be important for protein interactions by 
an E3 ligase or other interacting partner with this face of the homodimer and could be 
a mechanistic explanation for the essentiality of these residues in downstream protein 
function. Our work here has preliminarily defined a role for ubiquitination in the role 
of TBK1 regulation, more function experiments are required to determine if TBK1 is 
regulated by ubiquitination in the same way and to the same degree as IKK. 
 
TRAF2 is an E3-ubiqutin ligase that interacts and modifies IKK 
 We found that the IKK-interacting protein and RING finger domain protein 
TRAF2 catalyzed IKK ubiquitination in a manner dependent on the TRAF2 RING 
domain. Moreover, we found that suppression of TRAF2 decreased IKK 
ubiquitination, indicating that TRAF2 plays an essential role in the modification of 










Figure 2.10. Structure of TBK1 homodimer 
Overall structure of the TBK1 dimer. One molecule is colored in green(a) and one 
TBK1 molecule is colored in blue(b). Lys30 and Lys401 are shown on both 
molecules.  
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 TRAF2 is also known to interact in the same complex with TBK1, cIAP1, and 
TANK [33, 34]. Previously, TRAF2 has also been characterized in complex with  
RIP1 and cIAP1 to act as the E3 ligase that is responsible for RIP1 K63-linked 
ubiquitination [37]. Other studies have also shown cIAP1 and cIAP2 to also catalyze 
RIP1 ubiquitination [41]. Our work here has demonstrated that TRAF2, but not  
TRAF6, is required for IKK K63-linked ubiquitination in context of cancer. 
However, with ~600 E3 ubiquitin ligases in the human genome, further work is 
needed to determine if there are any other E3 ligases whose function may be 
sufficient to catalyze IKK ubiquitination. 
 Although IKK is a serine-threonine kinase potentially amenable to inhibition 
by small molecule inhibitors, developing inhibitors that specifically target particular 
kinases remains a challenge in the field. Our work here identifies TRAF2-mediated 
K63-linked ubiquitination as essential for IKK regulation and function. Recent work 
has proven that E3 ligases can also be targeted and inhibited by small molecule 
inhibitors [42]. In particular, small molecule inhibitors of the cullin-RING family of 
E3 ubiquitin ligases have been described [43, 44]. Thus, these observations not only 
provide new insights into the regulation of IKK but may also identify an alternative 
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Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene 
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ABSTRACT 
The non-canonical IKK family member IKK is essential for regulating antiviral 
signaling pathways and is a recently discovered breast cancer oncoprotein.  Although 
several IKK targets have been described, direct IKK substrates necessary for 
regulating cell transformation have not yet been identified.  Here, we performed a 
screen for putative IKK substrates using an unbiased proteomic and bioinformatic 
approach.  Using a positional scanning peptide library assay, we determined the 
optimal phosphorylation motif for IKK and used bioinformatic approaches to predict 
IKK substrates.  Of these potential substrates, serine 418 of the tumor suppressor 
CYLD was identified as a likely site of IKK phosphorylation.  We confirmed that 
CYLD is directly phosphorylated by IKK, and that IKK phosphorylates serine 418 
in vivo.  Phosphorylation of CYLD at serine 418 decreases its deubiquitinase activity 
and is necessary for IKK-driven transformation.  Together, these observations define 





Abundant evidence supports the view that chronic inflammation contributes to 
cancer initiation [1-3].  Subversion of many key regulatory steps involved in immune 
responses occurs in both hematopoietic and epithelial cancers.  For example, a large 
number of inflammatory mediators act as oncogenes, (IKK, IKK), tumor 
suppressors (CYLD), or pro-survival genes in specific cell types (p65, BCL-3) [1-3].   
One pathway that plays a key role in inflammation and cancer is the NF-B 
pathway.  Canonical, NF-B-driven, inflammation is initiated following cellular 
recognition of pathogens or proinflammatory cytokines.  These proinflammatory 
stimuli activate divergent signaling pathways, all of which ultimately converge to 
activate the IB kinase (IKK) complex [4].  The core IKK complex consists of the 
serine/threonine kinases IKK and IKK, as well as a regulatory subunit, NEMO.  
Upon activation by a diverse set of stimuli, this kinase complex phosphorylates the 
NF-B inhibitory protein IB, which facilitates ubiquitination of IB and 
subsequent proteasomal degradation [4].  Degradation of IB permits nuclear 
translocation of activated NF-B and the transcriptional activation of pro-
inflammatory target genes.  However, in addition to this canonical mechanism of NF-
B activation, several alternative signaling pathways also converge to activate NF-B 
[5-7].  Understanding these non-canonical regulatory mechanisms will provide 
insights into the interplay between inflammation and cancer.   
IKK (IB kinase ) is one such non-canonical IKK family member that plays 
a critical role in the regulation of interferon signaling pathways.  Both specialized 
membrane-bound Toll-like receptors and intracellular receptors which recognize viral 
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nucleic acids such as dsRNA activate this serine/threonine kinase [5, 6, 8, 9].  
Activated IKK (and the related kinase TBK1) then phosphorylates interferon 
response factors 3 and 7 (IRF3 and IRF7), allowing their nuclear translocation and the 
transcriptional upregulation of genes involved in the type I interferon response [10-
13].  IKK also phosphorylates STAT1 following activation by IFN [14].  The 
transcription factor NF-B is also activated by IKK, although the mechanism by 
which IKK regulates the canonical NF-B pathway is not well-understood [15, 16].   
We and others have identified IKK as a breast cancer oncogene amplified 
and overexpressed in over 30% of breast carcinomas and breast cancer cell lines [17-
19].  Forced expression of IKK substitutes for AKT and transforms immortal human 
cells, and suppression of IKK expression in breast cancer cell lines that harbor 
increased copy number leads to cell death [17].  Tumorigenicity induced by either 
IKK or AKT requires NF-B activation [17].  However, the specific substrates of 
IKK that are involved in cell transformation remain undefined.   
Familial cylindromatosis is an autosomal dominant disease characterized by 
the formation of benign skin tumors, primarily on the head and neck [20].  This 
disease results from inheritance of a gene encoding a truncation mutant of the tumor 
suppressor CYLD, followed by loss of heterozygosity [21].  Decreased CYLD 
expression has also been identified in both hepatocellular and colon cancer cell lines 
and tumors [22].  Furthermore, deletion of the CYLD locus has recently been shown 
to be associated with NF-B activation in multiple myeloma cell lines and patient 
tissues [23, 24].  CYLD is a deubiquitinating enzyme (DUB) that removes Lys63 
linked ubiquitin chains and acts as a negative regulator of NF-B signaling [25-27].  
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CYLD deubiquitinates several NF-B regulators, including TRAF2, TRAF6, and 
NEMO [25-27] as well as BCL3, a member of the NF-κB family of transcription 
factors [28].  Following ubiquitination, BCL-3 translocates from the cytoplasm to the 
nucleus where it heterodimerizes with the NF-B subunits p50 or p52 and activates 
the transcription of cyclin D, a key regulator of the G1 restriction point [29].  Similar 
to what is observed in kindreds afflicted with familial cylindromatosis, CYLD-/- mice 
develop benign skin tumors following exposure to UV light or TPA [28].  Other 
studies have shown that CYLD-/- mice also develop multi-organ hyperinflammation 
and have increased susceptibility to inflammation-induced tumors [30, 31].  Little is 
known, however, about how CYLD activity is regulated. 
Using a recently developed peptide library approach we determined the 
optimal motif for phosphorylation by IKK and then incorporated this information 
into a bioinformatic search for likely IKK protein substrates [32, 33].  Many of the 
predicted substrates are known components of inflammatory and/or oncogenic 
signaling pathways, including the tumor suppressor CYLD.  We show here that 
CYLD is a substrate of IKK and that phosphorylation of CYLD by IKK contributes 
to cell transformation.   
 
MATERIALS AND METHODS 
Antibodies, Plasmids, and Reagents.  Anti-Myc (9E10), anti-CYLD, anti-RIP2, and 
anti-GFP were obtained from Santa Cruz Technology.  Anti-Myc (rabbit) and anti-
GST (mouse) were from Cell Signaling Technology.  Anti-Flag (M2) and anti-HA 
were from Covance.  Anti-IKK and anti-actin were obtained from Sigma. Lentiviral 
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shRNA constructs targeting murine CYLD and GFP were obtained from the RNAi 
Platform of the Broad Institute of Harvard and MIT.  IKK-Tide, IKK-Y5A, and 
IKK-L8A were created and HPLC purified under contract by the Tufts University 
Core Facility.  The IB (IKK substrate) peptide was obtained from Upstate.  Myc-
CYLD and Myc-TRAF2 were created by PCR cloning into the BamHI site of the 
3XMyc (pEBB) vector.  GST-IKK was created by PCR cloning into the BamHI and 
NotI sites of the pEBG vector.  Flag-IKK and and Myr-Flag-IKK were used as 
described previously [17].  Myc-CYLD S418A, Myc-CYLD S547A, Myc-CYLD 
S772A, and GST-IKK K38A were created using a modification of the QuickChange 
Site-directed mutagenesis protocol (Stratagene).  pBabe-CYLD WT and site-directed 
mutants were created by subcloning into the BamHI site of the pBabe retroviral 
expression vector.  Myc NEMO K399R, OMNI-RIP2, HA-ubiquitin, and HA-Ub 
K63 only, and IB S32,36A (“superrepressor”) were used as described previously 
[17, 38].   
 
Cell Culture, Transfection, Immunoprecipitations, and Western Blotting.  HEK-
293T and MCF-7 cells were obtained from ATCC and were grown in DMEM 
containing 10% FBS.  NIH-3T3 cells were obtained from ATCC and grown in 
DMEM containing 10% bovine calf serum.  Transfection was performed by 
polyethylenimine.  For preparation of recombinant GST-IKK and GST-IKK K38A, 
and for preparation of all immunoprecipitations used in kinase assays and Western 
blots, cells were lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 
mM EDTA, 1 mM EGTA, 1 mM -glycerophosphate, 1 mM PMSF, 1 mM sodium 
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orthovanadate, 1 μg/mL leupeptin, 1 μg/mL pepstatin, and 10 nM Calyculin A.  For 
preparation of Myc-CYLD for mass spectrometry analysis, cells were lysed in the 
above buffer also containing 0.25% deoxycholic acid.  Immunoprecipitates for 
LC/MS/MS were washed in lysis buffer containing 1M NaCl prior to SDS-PAGE. 
 
In vitro kinase assays.  Recombinant GST-IKK, recombinant GST-IKK K38A, 
and immunoprecipitated Myc-CYLD were generated as described above.  Kinase 
buffer contained 50 mM Tris (pH 7.5), 12 mM MgCl2, 1 mM -glycerophosphate, 
100 μM ATP, and 10 μCi γ-32P-ATP/reaction.  Reactions were incubated at 30ºC for 
1h.  Recombinant GST-IKK and GST-IKK K38A used in the positional scanning 
peptide library assay were generated as described above and the assay was performed 
as described previously [32, 33]. 
 
Identification of in vivo Phosphorylation Sites by Mass Spectrometry. 
Identification: 
 
Coomassie stained SDS-PAGE gel bands containing CYLD isolated were excised and 
subjected to in-gel digestion and reversed-phase microcapillary LC/MS/MS using a 
LTQ 2D linear ion trap (Thermo Scientific, San Jose, CA) in data-dependent 
acquisition and positive ion mode at a flow rate of 275nL/min using a 10 cm C18 
microcapillary column. The column was equilibrated and peptides were loaded using 
0.1% acetic acid/0.9% acetonitrile/99% water then eluted with a gradient from 5% 
buffer B (acetonitrile) to 38% B, followed by 95% B for washing.  MS/MS spectra 
were searched against the reversed SwissProt protein database using Sequest 
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(Proteomics Browser Software, Thermo Scientific) with differential modifications for 
Ser, Thr and Tyr phosphorylation (+79.97) and Met oxidation (+15.99). 
Phosphorylation sites were identified if top ranking sequences matched to CYLD 
with the following Sequest scoring thresholds: 2+ ions, Xcorr ≥ 2.0, Sf ≥ 0.4, P ≥ 0; 
3+ ions, Xcorr ≥ 2.75, Sf ≥ 0.5, P ≥ 0 against the forward database. Passing MS/MS 
spectra were then manually inspected to be sure that all b- and y- fragment ions 
aligned with the assigned protein database sequence. The exact sites of 
phosphorylation were aided using GraphMod software (PBS). 
Targeted ion MS/MS: 
For sites of phosphorylation in protein regions exhibiting low amino acid coverage, a 
targeted ion MS/MS (TIMM) experiment was performed by setting the ion trap to 
perform MS/MS on expected m/z values for predicted peptides. Ser418 
(FHpSLPFSLTK) was not observed from a data dependent acquisition.  However, it 
was detected via database searching from a TIMM experiment targeting the doubly 
charged ion at m/z 628.81.  
 
NF-B reporter assays. 
MCF-7 cells: MCF-7 cells were transfected in 6-well dishes with an NF-B-
luciferase reporter (Clontech) and Renilla luciferase.  Transfection efficiency was 
standardized using the Renilla luciferase and assays were performed according to the 
manufacturer’s instructions (Promega). 
NIH-3T3 cells: NF-B activity was measured using the Dual-Glo Luciferase assay 
(Promega).  IKK-transformed NIH-3T3 cells stably expressing WT or mutant CYLD 
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were transiently transfected with pTRH1-NF-B-Luciferase reporter construct in 
parallel to pRL-SV40-Renilla. Additional ectopic WT and mutant CYLD was also 
introduced in these experiments using the expression constructs MYC-CYLD, Myc-
CYLD S418A, or Myc-CYLD S772A.  Luciferase values were normalized to Renilla 
values to calculate relative light units (RLU).    
 
In vitro cell transformation assays. 
Growth of NIH-3T3 cells in soft agar was determined by plating 5 X 104 cells in 
triplicate in 0.4% Noble agar and DMEM containing 10% bovine calf serum.  




A total of 2 X 106 cells were subcutaneously injected into immunodeficient mice 
(Balb/c Nude, Charles River Laboratories) anesthetized with isofluorane.  Two mice 
were used per group, and three injection sites were made per mouse.  Tumors were 
measured at 21 days post-injection. 
IKK phospho-substrate antibody. 
Rabbits were immunized with a phosphopeptide library with fixed residues 
corresponding to the IKK phosphorylation motif and antibodies were purified as has 





Determination of IKK substrate specificity 
 IKK has recently been identified as a breast cancer oncogene.  However, the 
mechanism by which IKK contributes to cell transformation is not known.  Since 
IKK is a serine/threonine kinase, we sought to determine whether the kinase activity 
of IKK is necessary for its oncogenic activity.  Wild-type IKK or kinase-dead IKK 
K38A was introduced into NIH-3T3 cells (Figure 3.1A).  We found that cells 
expressing WT IKK, but not IKK K38A, exhibited robust anchorage-independent 
colony growth (Figure 3.1B).  These results confirm that the kinase activity of IKK 
is necessary for its activity as an oncogene. 
While several IKK substrates involved in interferon signaling pathways have 
been identified, direct substrates required for the oncogenic functions of IKK have 
not been reported. To address this question, we utilized proteomic and bioinformatic 
approaches to perform an unbiased screen for likely IKK substrates.  Specifically, 
we used a positional scanning peptide library assay recently developed in this 
laboratory to identify the optimal phosphorylation motif for IKK [32, 33].  This 
assay employs 198 biotinylated peptide libraries.  Each library has a 50-50 mixture of 
serine and threonine fixed at the central position, and has one additional position 

















Figure 3.1. IKK mediates cell transformation  
(A)  NIH-3T3 cells were stably transduced with Flag-IKK, kinase-dead Flag-IKK 
K38A, or GFP control via lentiviral infection.  Immunoblot analysis shows similar 
IKK expression. F-IKK = Flag-IKK. (B) Flag-IKK or Flag-IKK K38A-
expressing NIH-3T3 cells generated in (A) were assayed for anchorage-independent 
growth.  Colony formation was examined after 21 days.  Expression of wild-type 
IKK, but not IKK K38A, induces anchorage-independent growth.  Error bars 
represent standard deviation (SD) for 3 independent experiments. 
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degenerate mixture of amino acids (excluding serine, threonine, and cysteine).  
Phosphothreonine and Phosphotyrosine were included at the fixed positions in order 
to facilitate the identification of kinases which have a requirement for priming 
phosphorylation events.  Using recombinant GST-IKK purified from HEK-293T 
cells, we performed kinase assays simultaneously on all 198 peptide libraries in 
solution using -32P-ATP.  Biotinylated peptides were captured with a streptavidin-
coated membrane and the relative preference for each amino acid at each position was 
determined by the relative level of radiolabel incorporation into the corresponding 
peptides. 
We found that IKK exhibits strong sequence selectivity at multiple positions 
surrounding the phosphorylation site.  IKK strongly prefers substrates with a 
hydrophobic residue at the +1 position relative to the phosphorylation site (Figures 
3.2A and 3.2E).  This kinase also exhibits strong sequence selectivity for aromatic 
residues at the -2 position, and for bulky hydrophobic residues at the +3 position 
(Figures 3.2A and 3.2E).  A kinase-dead IKK K38A does not exhibit selectivity at 
these positions, confirming that peptides were not being phosphorylated by a 
contaminating kinase (Figure 3.2B). 
 To validate this motif, we generated a consensus peptide substrate, IKK-
Tide, and measured the phosphorylation of peptides bearing individual alanine 
substitutions.  By comparing these results to those obtained using the consensus 
sequence we confirmed that substitution of amino acids at the +1 or -2 positions 
resulted in a decrease in the efficiency of peptide phosphorylation (Figure 3.2C).  
This motif has similarities to the sequence surrounding the autophosphorylation site  
 79
  
Figure 3.2: Identification of the optimal IKK phosphorylation motif 
(A-B)  Recombinant IKK or kinase-dead IKK K38A was used to phosphorylate 
198 peptide libraries in individual kinase assays.  The general sequence for these 
libraries is Y-A-X-X-X-Z-X-S/T-X-X-X-X-A-G-K-K-biotin (Z = fixed amino acid, X 
= equimolar mixture of amino acids excluding Ser, Thr, and Cys).  After binding to a 
streptavidin-coated membrane, phosphorylation was visualized by the incorporation 
of 32P.  WT IKK (A) gave a strong, consistent motif.  No motif could be identified 
using IKK K38A (B). (C and D)  Individual peptides were phosphorylated with 
recombinant IKK(C) and IKK(D).  Phosphorylation is shown as a percentage of the 
rate of phosphorylation of IKK-Tide, the optimal peptide substrate for IKK as 
determined in (A).  Alteration of critical amino acids to alanine decreased peptide 
phosphorylation.  A peptide corresponding to the sequence surrounding Ser32 and 
Ser36 of IB was not efficiently phosphorylated by IKK.  Error bars depict SD. 
(E)  Primary and secondary selections determined from IKK phosphorylation motif.   
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in the activation loop of IKK (DEKFVS172VYGTE) due to the aromatic residue at -2 
and aliphatic at +1, although this site is predicted to be suboptimal due to the lack of 
an aromatic residue at +3 [15]. 
IKK has been shown to phosphorylate one of the essential serines on IκB in 
vitro, but in vivo phosphorylation of IκB by this kinase has not been described [15].  
Therefore, the role of IKK in IκB phosphorylation and degradation remains 
unclear.  To examine this question, we performed kinase assays using a peptide 
substrate corresponding to the sequence surrounding Ser32 and Ser36 of IκB.  This 
peptide contains two potential phosphorylation sites, but neither site is within a 
sequence context that matches the optimal motif for IKK.  We found that this 
peptide was a poor in vitro substrate for IKK when compared with the optimal 
peptide determined from the peptide library screen (Figure 3.2E).  In contrast, when 
recombinant GST-IKK was used to phosphorylate the same set of peptides, the 
IκB peptide was phosphorylated by IKK substantially more efficiently than IKK-
Tide (Figure 3.2D).  These observations suggest that IκB is unlikely to be an 
important physiological substrate of IKK.  We recently demonstrated that, like 
IKK, IKK prefers aromatic residues at the -2 position and hydrophobic residues at 
the +1 position [34].  However, the phosphorylation motifs for these kinases differ at 
the -4, -5, and +3 positions.  Taken together, these observations demonstrate that 
while the substrate specificities of IKK and the related kinase IKK have 
overlapping characteristics, the optimal substrate peptides for these kinases differ in 
substantial ways and therefore be predicted to have different (though possibly 
overlapping) in vivo substrates. 
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Prediction of IKK substrates 
Spot intensities from the peptide library screen were then quantified and 
converted into a matrix which could be used with the bioinformatic search engine 
Scansite (Table 3.1).  Scansite (http://scansite.mit.edu) allows proteome-wide 
searches for sites which best match the data provided by the input matrix [35, 36].  
Table 3.2 shows top-scoring candidate IKK substrates obtained following the 
Scansite analysis.  All of these potential phosphorylation sites scored in the top 0.05% 
of sites in the SwissProt database.  Interestingly, a large number of predicted IKK 
substrates are known to be involved in inflammatory and/or oncogenic signaling 
pathways.  Of these potential substrates, the deubiquitinating enzyme CYLD was of 
particular interest, as it has been shown to have roles as both an inflammatory 
mediator and tumor suppressor, functions that could be downstream of IKK [21].  
Our bioinformatic analysis predicted that CYLD is likely to be phosphorylated by 
IKK at Ser418.   
 
CYLD is phosphorylated by IKK at Ser418 
To further facilitate the identification of novel IKK substrates we raised 
antibodies against a collection of phosphopeptides biased towards the optimal IKK 
phosphorylation motif.We verified that these antibodies recognize known IKK 
substrates in a kinase-dependent manner (data not shown).  These antibodies were 
then used to determine whether CYLD is phosphorylated at a site matching the IKK 






Table 3.1. IKK specificity values 
 
Following the positional scanning peptide library assay, phosphate incorporation for 
each amino acid at each position was quantified using the ImageQuant 5.2 software 
from Molecular Dynamics.  The phosphate incorporation for each amino acid was 
then divided by the average phosphate incorporation for the amino acids in that row.  





Table 3.2. Candidate IKK substrates 
 
A Scansite matrix was created from IKK specificity values (Table 3.1).  Scansite 
(scansite.mit.edu) was then used to search the SwissProt database for sites which 
correspond to the IKK phosphorylation motif.  Included sites scored in the top 
0.05% of sites searched. 
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CYLD (Myc-CYLD) and either GST-IKK WT or kinase-dead IKK K38A.  CYLD 
was immunoprecipitated via its Myc tag and immunoblotted with the anti-IKK 
phospho-substrate antibody.  Figure 3.3A shows that the phospho-substrate antibody 
blotted CYLD which had been transfected with WT IKK, but not IKK K38A.  
CYLD treated with calf-intestinal phosphatase (CIP) following cotransfection with 
IKK was no longer recognized by the phospho-substrate antibody, confirming that 
the IKK phospho-substrate antibody specifically recognizes phosphorylated CYLD 
(Figure 3.3B). 
In order to determine whether IKK can directly phosphorylate CYLD, an in 
vitro kinase assay was performed.  Wild-type GST-IKK or GST-IKK K38A was 
purified from HEK-293T cells.  Myc-CYLD was separately transfected into HEK-
293T cells and immunoprecipitated.  When the CYLD immunoprecipitate was 
incubated in an in vitro kinase assay with WT IKK, strong phosphorylation of 
CYLD was observed (Figure 3.3C).  This phosphorylation was not observed in the 
presence of IKK K38A.   
To determine whether IKK and CYLD physically interact, Myc-CYLD was 
cotransfected into HEK-293T cells expressing GST- IKK WT or K38A.  CYLD was 
immunoprecipitated via its Myc tag and these immune complexes were blotted with 
an anti-GST antibody to identify IKK.  In CYLD immune complexes we identified 
both WT and kinase-dead IKK (Figure 3.4A).  Moreover, when we performed the 
reciprocal experiment, we found that Myc-CYLD was also observed in the IKK 































Figure 3.3. IKK phosphorylates CYLD at a site corresponding to the IKK 
phosphorylation motif 
(A)  Myc-CYLD was cotransfected with GST-IKK WT or K38A into HEK-293T 
cells.  Myc-CYLD was immunoprecipitated and immune complexes were 
immunoblotted with an IKK phospho-substrate antibody.  CYLD was recognized by 
the phospho-substrate antibody when cotransfected with WT IKK, but not kinase-
dead IKK. (B)  Myc-CYLD was transfected into HEK-293T cells alone or with 
GST-IKK.  CYLD was immunoprecipitated with an anti-Myc antibody.  
Immunoprecipitates were divided into two samples and treated with either Calf-
intestinal phosphatase (CIP) or water (as a control) for 45 min at 37ºC.  Samples were 
then blotted with an IKK phospho-substrate antibody (C)  Recombinant GST-IKK 
or IKK K38A was purified from HEK-293T cells.  Myc-CYLD was transfected 
separately into HEK-293T cells and immunoprecipitated.  CYLD immune complexes 
























Figure 3.4. CYLD physically interacts with IKK 
 Myc-CYLD was cotransfected into HEK-293T cells with GST-IKK WT or GST-
IKK K38A.  (A) Lysates were subjected to immunoprecipitation with an anti-Myc 
antibody and immunoprecipitates were blotted with an anti-GST antibody.  (B) 
Lysates were subjected to precipitation with glutathione-conjugated Sepharose beads 
and precipitates were blotted with an anti-Myc antibody.  CYLD interacts with both 
WT and kinase-dead IKK. 
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While CYLD Ser418 was predicted by Scansite to be the optimal site for 
IKK phosphorylation (ENRFHS418LPFSL), two additional serines within the CYLD 
sequence were potential, though less optimal, IKK phosphorylation sites 
(DSRFAS547LQPVS and KKIFPS772LELNI).  Therefore, we used mass spectrometry 
to determine which residue(s) of CYLD is phosphorylated in vivo.  Myc-CYLD and 
GST-IKK were cotransfected into HEK-293T cells.  CYLD was 
immunoprecipitated, subjected to SDS-PAGE, and Coomassie stained (Figure 3.5A).  
The band corresponding to Myc-CYLD was excised, digested with trypsin or 
chymotrypsin, and subjected to microcapillary LC/MS/MS.  A phosphopeptide 
consistent with phosphorylation at Ser418 was identified.  This analysis confirmed 
that CYLD is phosphorylated at Ser418, the same site predicted by our bioinformatic 
analysis (Figure 3.5B).  Ser418 is evolutionarily conserved in all sequenced 
mammals, as well as Gallus gallus and Xenopus tropicalis (Figure 3.5C).  In addition, 
the -2F, +1L, and +3F relative to Ser418 (which correspond to the IKK 
phosphorylation motif) are also conserved, providing further evidence for the 
evolutionary importance of this phosphorylation site. 
To further verify that Ser418 is the critical site phosphorylated by IKK, we 
created Myc-epitope tagged mutants of CYLD at Ser418 (S418A), Ser547 (S547A), 
and Ser772 (S772A).  We introduced wild-type CYLD or each of these mutants into 
HEK-293T cells alone or with GST-IKK and isolated CYLD immune complexes.  
Mutation of either Ser547 or Ser772 did not affect recognition of CYLD by the IKK 
phospho-substrate antibody (Figure 3.6A).  However, Myc-CYLD S418A was no 







































Figure 3.5  Identification of CYLD phosphorylation site 
(A) Myc-CYLD was cotransfected into HEK-293T cells with GST-IKK.  Myc-
CYLD was immunoprecipitated and the immunoprecipitate was subjected to SDS-
PAGE followed by Coomassie staining. (B)The band corresponding to CYLD was 
excised from the gel, and digested with trypsin and chymotrypsin.  Phosphorylation 
sites were mapped by microcapillary LC/MS/MS, resulting in 85% coverage of the 
CYLD amino acid sequence.  A phosphopeptide consistent with phosphorylation at 





















Figure 3.6.  CYLD is phosphorylated by IKK at Ser418. 
(A)  Cell were transfected as indicated. Lysates were subjected to 
immunoprecipitation with an anti-Myc antibody and immunoprecipitates were blotted 
with an anti-IKK phospho-substrate antibody. (B)  Myc-CYLD WT or Myc-CYLD 
S418A was cotransfected into HEK-293T cells with GST- IKK.  Lysates were 
subjected to immunoprecipitation with an IKK phospho-substrate antibody.  
Immunoprecipitates were blotted with an anti-Myc antibody. (C)  Endogenous CYLD 
was immunoprecipitated from IKK-transformed NIH-3T3 cells generated in Figure 
3.1A.  Immunoprecipitates were blotted with an IKK-phospho-substrate antibody. 
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IKK (Figure 3.6A).  In addition, when we introduced Myc-CYLD or Myc-CYLD 
S418A with IKK into HEK-293T cells and performed an immunoprecipitation using 
the IKK phospho-substrate antibody, we found that wild-type Myc-CYLD, but not 
Myc-CYLD S418A, was efficiently immunoprecipitated by the IKK phospho-
substrate antibody (Figure 3.6B).  Finally, endogenous CYLD was 
immunoprecipitated from IKK-transformed NIH-3T3 cells utilized in Figure 3.1.  
Immunoblotting with the IKK phospho-substrate antibody revealed that CYLD is 
indeed phosphorylated in cells transformed by IKK, but not in cells expressing IKK 
K38A (Figure 3.6C).  Together, these data confirm that CYLD Ser418 is 
phosphorylated in vivo in the presence of IKK. 
It has been reported that Ser418 of CYLD is a substrate of the canonical IKK 
family members, IKK and IKK [37].  Therefore, in order to determine which IKK 
family member(s) can most efficiently phosphorylate CYLD, we cotransfected Myc-
CYLD with individual IKK family members fused to GST.  CYLD was 
immunoprecipitated using an anti-Myc antibody and blotted using the anti-IKK 
phospho-substrate antibody.  Figure 3.7 shows that CYLD was efficiently 
phosphorylated in cells transfected with IKK.  In contrast, CYLD is phosphorylated 
inefficiently in cells transfected with IKK and IKK, even when greater than 5X 
more kinase is present (Figure 3.7).  While it is therefore possible for any of these 
IKK family members to phosphorylate Ser418 of CYLD, CYLD is a much better 
substrate for IKK than for IKK or IKK.  Our analysis of IKK and IKK peptide 















Figure 3.7. Phosphorylation of CYLD by IKK family members. 
Myc-CYLD was cotransfected into HEK-293T cells with IKK, IKK, or IKK (WT 
or kinase-dead).  CYLD was immunoprecipitated via its Myc tag, and 




largely different, though possibly overlapping, substrate pools (Figures 3.2C and 
3.2D). 
 
IKK-mediated phosphorylation of CYLD at S418 facilitates transformation 
Since CYLD is a known tumor suppressor and IKK is a newly-discovered 
oncoprotein [17, 21, 28], we hypothesized that phosphorylation of CYLD by IKK 
might play a role in the regulation of IKK-mediated cell transformation.  In Figure 
3.1 we show that forced expression of IKK induces a tumorigenic phenotype in 
NIH-3T3 cells.  To determine whether suppression of CYLD also induced cell 
transformation in this experimental model, we suppressed murine CYLD using two 
distinct short hairpin RNAs (shRNA), each of which strongly suppresses endogenous 
levels of CYLD (Figure 3.8A).  Suppression of CYLD induced substantial anchorage-
independent growth of NIH-3T3 cells when compared to control NIH-3T3 cells 
(Figures 3.8B and 3.8C).   
To determine whether CYLD phosphorylation is required for IKK-mediated 
transformation, we generated IKK-transformed NIH-3T3 cells that stably express 
wild-type CYLD, CYLD S418A, or CYLD S772A (Figure 3.9A).  We found that 
Flag-epitope tagged IKK-expressing cells exhibited robust anchorage-independent 
growth that was 4-fold above that observed in control NIH-3T3 cells or cells 
expressing WT CYLD or CYLD S772A (Figure 3.9B).  In contrast, in tumorigenic 
cells expressing Flag-epitope-tagged IKK, co-expression of CYLD S418A 
suppressed anchorage-independent growth (Figure 3.9B).  A similar result was 




















Figure 3.8. Suppression of CYLD protein expression is sufficient to induce 
transformation.  
(A) Two distinct shRNA constructs targeting murine CYLD (shCYLD1 and 
shCYLD2) were transduced into NIH 3T3 cells via lentiviral infection. Two shRNAs 
targeting GFP (shGFP1 and shGFP49) were used as controls. Both shCYLD1 and 
shCYLD2 induce substantial knockdown of endogenous CYLD. 
(B and C) Anchorage-independent growth of NIH 3T3 cells was assessed following 
suppression of endogenous CYLD with shCYLD1 or shCYLD2 for 21 days. (B) 
Colony number and (C) Colony formation (at 103 magnification) were examined. 



















Figure 3.9. CYLD phosphorylation at serine 418 is important for IKK-mediated 
transformation.   
(A) IKK-transformed NIH-3T3 cells were stably transduced with WT-CYLD, 
CYLD S418A, CYLD S772A, or vector control.  Immunoblot analysis for CYLD and 
IKK were performed. (B) Flag-IKK transformed NIH-3T3 cells expressing WT 
CYLD or CYLD mutants generated in (A) were assayed for anchorage-independent 
growth.  Colony formation was examined after 21 days. (C) IKK-transformed NIH-
3T3 cells expressing WT CYLD, CYLD S418A, CYLD S772A, or GFP control were 
subcutaneously introduced into immunodeficient mice.  Relative tumor volume was 
assessed at 21 days post injection. Astericks indicates statistical significance as 
determined by a student’s t-test (p≤ 0.05). 
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IKK-induced tumorigenicity.  Introduction of IKK-transformed NIH-3T3 cells into 
immunodeficient animals yielded tumor formation at a high penetrance (Figure 3.9C, 
data not shown). While expression of WT CYLD or CYLD S772A failed to 
significantly alter tumorigenicity, expression of CYLD S418A led to statistically-
significantly smaller tumors (p<0.05) (Figure 3.9C). Taken together, these findings 
demonstrate that phosphorylation of CYLD by IKK at serine 418 is necessary for 
IKK to fully induce transformation.    
 
Phosphorylation of CYLD at Ser418 decreases CYLD activity 
CYLD is a deubiquitinating enzyme which can remove Lys63 linked ubiquitin 
chains from a large number of proteins, including the inflammatory mediators 
TRAF2, TRAF6, and NEMO, as well as the pro-proliferation transcription factor 
BCL-3 [25-28].  Removal of these ubiquitin chains by CYLD inactivates these 
substrates, downregulating inflammatory signaling and progression through the cell 
cycle.  Upon loss of CYLD protein level or activity, therefore, cell transformation is 
hypothesized to occur following the accumulation of a variety of ubiquitinated 
species, which leads to both increased cell proliferation and the increased 
transcription of NF-κB-regulated anti-apoptotic factors.   Therefore, we sought to 
determine the effect of CYLD phosphorylation on ubiquitination of known CYLD 
substrates.   
TRAF2 is a critical NF-κB mediator ubiquitinated via Lys63-linked ubiquitin 
chains following stimulation with TNF, and CYLD removes these ubiquitin chains 
to prevent uncontrolled TNF-induced inflammation.  To determine the effect of 
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CYLD phosphorylation on TRAF2 ubiquitination, HEK-293T cells were transfected 
with Myc-epitope tagged TRAF2 in combination with GFP-WT CYLD or CYLD 
S418A and GST-IKK.  In order to examine only changes in Lys63 linked ubiquitin 
chains, cells were also transfected with an HA-tagged ubiquitin construct which has 
all lysines mutated to arginine except for Lys63 (HA-Ub-K63).  Cells were stimulated 
with TNF for 10 minutes prior to lysis.  Lysates were immunoprecipitated with an 
anti-Myc antibody and blotted with an anti-HA antibody.  As expected, CYLD 
efficiently removed Lys63-linked ubiquitin chains from TRAF2 (Figure 3.10A).  
Interestingly, coexpression of IKK blocked CYLD-mediated deubiquitination of 
TRAF2, demonstrating that phosphorylated CYLD exhibited less deubiquitinating 
activity than unphosphorylated CYLD.  In contrast, cotransfection of CYLD S418A 
with IKK did not block deubiquitination of TRAF2 (Figure 3.10A).  Thus, IKK 
regulates the deubiquitination of TRAF2 by CYLD. 
The IKK regulatory subunit NEMO also undergoes Lys63-specific 
ubiquitination at Lys285 when coexpressed with RIP2, resulting in increased NF-κB 
activity [38, 39].  CYLD efficiently removes these RIP2-induced ubiquitin chains 
from NEMO [38].  To determine whether phosphorylation of CYLD also affects 
RIP2-induced NEMO ubiquitination, HEK-293T cells were cotransfected with Myc-
NEMO, OMNI-RIP2, HA-Ubiquitin, GFP-CYLD, and GST-IKK.  As expected, 
cotransfection of RIP2 with NEMO increased NEMO ubiquitination, and this 
ubiquitination was suppressed by CYLD (Figure 3.10B).  However, cotransfection of 




















Figure 3.10. Phosphorylation of CYLD at Ser418 decreases CYLD DUB activity 
(A)  HEK-293T cells were transfected with HA-Ub K63, Myc-TRAF2, GFP-CYLD 
WT or S418A, and GST-IKK.  Cells were stimulated with 10 ng/mL TNF for 10 
minutes prior to lysis.  TRAF2 was immunoprecipitated using an anti-Myc antibody, 
and immunoprecipitates were blotted with an anti-HA antibody. (B)  HEK-293T cells 
were transfected with HA-Ubiquitin, Myc-NEMO, OMNI-RIP2, GFP-CYLD WT or 
S418A, and GST-IKK.  NEMO was immunoprecipitated with an anti-Myc antibody 
and immunoprecipitates were blotted with an anti-HA antibody.  
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phosphorylation of CYLD leads to decreased deubiquitinase activity.  As in Figure 
3.10A cotransfection of CYLD S418A with IKK did not lead to suppression of 
NEMO ubiquitination (Figure 3.10B).  Together, these observations demonstrate that  
phosphorylation of CYLD at Ser418 leads to decreased CYLD deubiquitinase 
activity. 
We next sought to determine what effect this phosphorylation exerts on NF-
κB activity.  We have shown previously that MCF-7 cells express elevated levels of 
endogenous IKK [17].  These cells were transiently transfected with Myc-TRAF2 
alone or in combination with Myc-CYLD, Myc-CYLD S418A, or Myc-CYLD 
S772A, and we performed a NF-κB-luciferase reporter assay.  In cells expressing 
TRAF2 alone, we found substantial (14.9 fold) activation of the NF-κB reporter 
(Figure 3.11A).  Co-transfection with a sub-saturating amount of WT CYLD or 
CYLD S772A resulted in an approximately 50% decrease in TRAF2-induced NF-κB 
activation.  However, co-transfection with CYLD S418A resulted in a statistically 
significantly larger decrease in NF-κB reporter activity (p<0.05) (Figure 3.11A).  
These results demonstrate that phosphorylation of CYLD at Ser418 suppresses CYLD 
activity, which in turn results in an increase in NF-κB transcriptional activation.  
To further validate this observation, we assessed whether CYLD 
phosphorylation by IKK modulates NF-κB activity in the context of transformation.  
NF-κB luciferase reporter activity was measured in IKK-transformed NIH-3T3 cells 
overexpressing WT or mutant CYLD (S418A and S772A).  IKK-transformed cells 
exhibited strong NF-κB activation in comparison to control cells, and the introduction 
of WT CYLD and S772A failed to induce a substantial change in NF-κB activity  
 99
 Figure 3.11. Phosphorylation of CYLD at Ser418 decreases CYLD activity. 
(A)  MCF-7 cells were transfected with an NF-B–luciferase reporter gene, CMV-
driven Renilla luciferase (to standardize transfection efficiency), and TRAF2 (200 ng) 
either alone or in combination with a subsaturating amount of Myc-CYLD WT, Myc-
CYLD S418A, or Myc-CYLD S772A (5 ng).  An NF-B–luciferase reporter assay 
was performed at 24 h posttransfection. Each experiment was performed four times 
with similar results. TRAF2 alone increased NF-B reporter activation 14.9 fold. 
CYLD S418A inhibited the NF-B response induced by TRAF2 more efficiently than 
WT CYLD or CYLD S772A.  Error bars represent SD.  Astericks indicates statistical 
significance (p<0.05). (B)  IKK-transformed NIH-3T3 cells stably expressing WT or 
mutant CYLD were transiently transfected with pTRH1-NF-B-Luciferase reporter 
construct in parallel to pRL-SV40-Renilla. Additional ectopic WT and mutant CYLD 
was also introduced in these experiments as described in the Materials and Methods.  
Luciferase activity was assessed 2 days post transfection.     Representative of 4 
separate experiments.  Error bars represent SD. (C)  Anchorage-independent growth 
of NIH-3T3 cells was assessed following suppression of endogenous CYLD with 
shCYLD1 and simultaneous expression of an NF-B “superrepressor” (IB 
S32,36A) for 21 days.  Error bars represent SD for 3 independent experiments. 
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(Figure 3.11B).  As observed in MCF-7 cells, however, CYLD S418A more strongly 
inhibited IKK-induced NF-κB activation.  These findings indicate that IKK-
mediated phosphorylation of CYLD at serine 418 plays a role in the observed 
activation of NF-κB.  As the decrease in NF-κB activation observed in the presence 
of CYLD S418A was not as robust as the decrease in transformation, it is likely that 
NF-κB is not the only pathway affected by phosphorylation of CYLD.  However, 
these findings suggest that increased the regulation of CYLD phosphorylation by 
IKK contributes to the NF-κB activity necessary for IKK-mediated cell 
transformation. 
To further confirm that cell transformation mediated by CYLD suppression 
was NF-κB dependent, we utilized the NIH-3T3 cells expressing shRNAs targeting 
murine CYLD which were described in Figure 3.8.  When a non-phosphorylatable 
IκB mutant (IκB S32,36A), which acts as an NF-κB “superrepressor,” was stably 
expressed in these cells, we found a dramtatic reduction in anchorage-independent 
colony growth (Figure 3.11C).  Thus, suppression of CYLD induces NF-κB-
dependent cell transformation similar to that induced by overexpression of IKK. 
 
DISCUSSION 
IKK plays a central role in regulating innate immunity and also acts as an 
oncogene in a significant fraction of breast cancers.  To gain a deeper understanding 
of the role(s) of IKK in these biological processes, we used an unbiased proteomic 
and bioinformatic approach, which allowed us to identify the optimal substrate 
phosphorylation motif for IKK. Based on these findings, a proteome-wide search for 
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sites that correspond to the IKK phosphorylation motif then led to the identification 
of a large number of putative IKK substrates. 
Of the candidate IKK substrates identified, many have known roles in 
inflammatory and/or oncogenic signaling pathways (Table 3.2).  In particular, serine 
418 of the deubiquitinase and tumor suppressor CYLD emerged as a very likely site 
of IKK phosphorylation.  Here we showed that IKK directly phosphorylates CYLD 
and have used mass spectrometry and an IKK phospho-substrate antibody to show 
that Ser418 of CYLD is, in fact, the in vivo site phosphorylated by IKK.  While it 
has been reported previously that IKK and IKK are capable of phosphorylating 
Ser418 of CYLD [37], we demonstrated that CYLD is phosphorylated much more 
efficiently by IKK than by either of the canonical IKKs.   
Upon finding that an oncoprotein is capable of strongly phosphorylating a 
known tumor suppressor, we predicted that CYLD phosphorylation at Ser418 might 
play an important role in cell transformation.  Indeed, we found that introduction of 
CYLD S418A suppressed anchorage-independent growth in IKK-transformed NIH-
3T3 cells and hindered IKK-driven tumor growth.  The data presented here therefore 
define the one potential mechanism by which IKK induces tumorigenesis.  Further 
examination showed that phosphorylation of CYLD at S418 decreases its 
deubiquitinase activity and increases NF-κB activation.  Activation of NF-κB 
therefore appears to be one important mechanism by which CYLD phosphorylation 
regulates cell transformation.  As CYLD also has functions independent of NF-κB it 
is likely that other signaling pathways also may be involved. Moreover, we recognize 
that IKK may also modulate other substrates in addition to CYLD during cell 
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transformation. Thus, although further work will be necessary to evaluate the full 
mechanisms by which IKK and CYLD contribute to transformation, these 
observations connect an oncogene and tumor suppressor that both regulate NF-κB to 
cell transformation.   
The role of chronic inflammation in the development of inflammation-related 
cancers is well-known, but the mechanisms by which inflammatory mediators cause 
cell transformation are poorly understood [1-3].  For kinases involved in these 
signaling pathways, such as the anti-viral mediator and oncoprotein IKK, our 
inability to identify the complete repertoire of intracellular substrates has hindered 
progress towards understanding how these enzymes exert their oncogenic effects.  
The techniques described here, involving the identification of the phosphorylation 
motif for a kinase, followed by development of a phospho-substrate antibody and 
bioinformatic prediction of substrates, can provide an efficient and unbiased method 
for the identification and validation of physiologically relevant kinase substrates.  We 
have validated this method through the identification of CYLD as a novel IKK 
substrate and have shown that CYLD phosphorylation is necessary for full IKK-
mediated anchorage-independent growth.  As expression of CYLD S418A does not 
completely suppress IKK-driven cell transformation, CYLD is unlikely to be the 
only IKK substrate important for cell transformation.  However, the strength of the 
approach described here, as opposed to more targeted methods of substrate 
identification, is that it has simultaneously identified a large number of other 
potentially important IKK substrates.  Available in vitro assays should allow other 
putative substrates to be efficiently tested for their ability to modulate IKK-driven 
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cell transformation, leading to both an increased understanding of how IKK controls 
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NF-B transcription factors are central regulators of inflammation and when 
dysregulated contribute to malignant transformation. IB kinase  (IKK, IKKi, 
IKBKE) is a breast oncogene that is amplified and overexpressed in 30% of breast 
cancers and drives transformation in a NF-B-dependent manner. Here we identify 
TRAF2 as an oncogenic substrate of IKK. IKK interacts with and phosphorylates 
TRAF2 at Ser11 in vitro and in vivo. This activity promotes Lys63-linked TRAF2 
ubiquitination, NF-B activation and is essential for IKK-transformation. Breast 
cancer cells that depend on IKK expression for survival are also dependent on 
TRAF2. This work defines TRAF2 phosphorylation as a key component of IKK-
induced mammary epithelial cell transformation. 
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INTRODUCTION 
 NF-B activation plays a key role in innate immunity and inflammation. 
Several lines of evidence indicate that dysregulation of NF-B signaling also 
contributes to malignant transformation through both cell autonomous and cell non-
autonomous mechanisms. Although cancers associated with chronic inflammation are 
frequently dependent on aberrant NF-B activity induced by the tumor 
microenvironment [1-4], somatic mutations in components of the NF-B pathway 
that lead to constitutive NF-B activation also contribute directly to tumorigenicity.  
 Activation of the canonical NF-B pathway is facilitated by the recruitment of 
receptor associated adaptor molecules such as TNF receptor associated factors, 
TRAFs [5]. TRAF proteins mediate the formation of protein complexes that activate 
the classical IB kinase (IKK) complex, consisting of the catalytic kinases IKK and 
IKK, and the regulatory subunit IKK/NEMO. IKK complex activation triggers 
proteasomal-mediated degradation of the key inhibitory molecule IB that, in turn, 
permits nuclear translocation of NF-B dimers. In addition to this canonical mode of 
activation in response to TNF, an array of inflammatory stimuli activate several 
signaling pathways that converge to activate NF-B [6].  
IKK (IB kinase , encoded by IKBKE) is a non-canonical IKK family 
member that activates both interferon and NF-B signaling. In response to viruses, 
both IKK and another non-canonical IKK, TBK1, form a complex to phosphorylate 
interferon regulatory factors 3 and 7 (IRF3 and IRF7) [7]. This activity is essential for 
the nuclear translocation of IRF3 and IRF7 and transcriptional activation of type I 
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interferon genes [8]. In addition to its role in innate immunity, IKBKE is also a breast 
oncogene that is amplified and overexpressed in approximately 30% of breast cancers 
[9]. Suppression of IKBKE induces apoptosis in breast cancer cell lines that harbor 
increased IKBKE copy number. IKK overexpression induces malignant 
transformation in immortalized human and murine cells in a NF-B dependent 
manner [9].  
We recently employed a scanning peptide library screen and Scansite 
bioinformatic analysis to identify an IKK kinase recognition motif and potential 
IKK substrates. Using this combined proteomic and bioinformatic approach, we 
identified the familial tumor suppressor CYLD to be an IKK substrate involved in 
cell transformation [Chapter 3, 10]. As a deubiquitinase, CYLD acts as a negative 
regulator of NF-B signaling. Phosphorylation of CYLD by IKK at serine 418 
inactivates CYLD function and leads to NF-B activation. Although this 
phosphorylation event was necessary for IKK-mediated transformation, cells 
rendered tumorigenic by IKK expression were only partially dependent on CYLD 
for transformation. These observations suggested that IKK regulates other effectors 
that participate in NF-B pathway activation and transformation.  
Here we identify TRAF2, an adaptor molecule that assembles active NF-B 
signaling modules, as a substrate of IKK. IKK phosphorylates TRAF2 at Ser11 and 





MATERIALS AND METHODS 
Antibodies, Plasmids, and Reagents. The antibodies used include: Myc (clone 4A6) 
(Millipore), HSP90, Lamin A/C, p50, p52, CIAP1, TRAF2 (Rabbit) and TANK (Cell 
Signaling Technologies), V5-HRP (Invitrogen), Ubiquitin (Santa Cruz 
Biotechnology), IKK and -actin (Sigma-Aldrich), HA (Clone12C5) (Boehringer 
Mannheim), a mouse monoclonal TRAF2 antibody (Imgenex). The IKK phospho-
substrate antibody was previously described [10]. The phospho-TRAF2 (Ser 11) 
antibody was a gift from Dr. Hasem Habelhah. Anti-V5 affinity gel agarose was 
obtained from Sigma- Aldrich. 
 Myc-TRAF2 was created by PCR cloning into the BamHI site of the 3XMyc 
(pEBB) vector. GST-IKK, GST-K38A, and have been described [10]. Flag-IKK 
and Myr-Flag-IKK were used as described [9]. Myc-TRAF2 S11A, Myc-TRAF2 
S102A, Myc-TRAF2 S274A, Myc-TRAF2 S327A, and Myc-TRAF2 S408A and 
were created using QuickChange site-directed mutagenesis protocol (Stratagene). 
pWZL-TRAF2 WT and site-directed mutants were created by subcloning into the 
BamHI site of the pWZL-Blast retroviral expression vector(s). V5-GFP, V5-TRAF2, 
V5-TRAF2 S11A, and V5-TRAF2 S102A were generated by gateway cloning into 
the pLEX-V5-Blast lentiviral construct. HA-ubiquitin, HA-Ub K63-only, and HA-Ub 
K48-only were used as described previously [9, 11]. shIKK and shCYLD lentiviral 
constructs have been described [9, 10]. Additional shRNA constructs were obtained 
from the RNAi Consortium (Broad Institute) and include pLKO-shTRAF2#1, pLKO-
shTRAF#2, pLKO-shGFP, pLKO-shRFP, pLKO-shLacZ, and pLKO-shLuc. 
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Cell Culture, Transfection, Immunoprecipitation, Subcellular Fractionation, and 
Immunoblotting. HEK293T, MDA-MB-453, MCF-7, RKO cells were obtained from 
ATCC and were grown in DMEM containing 10% FBS. NIH3T3 cells were obtained 
from ATCC and grown in DMEM containing 10% bovine calf serum. HA1EM and 
HMLEM cells have been described [9]. BT549, BT474, MCF-7, MDA-MB-453, 
T47D, and ZR-75-1 were obtained from ATCC and maintained in RPMI1640 
containing 10% FBS. SUM52 cells were maintained in HamsF-12:MEGM(1:1) with 
10% FBS. Transfection experiments were performed using Fugene (Roche). 
Immunoprecipitations and immunoblotting experiments were conducted as described 
[12, 13]. 
 
In vitro kinase assays. Recombinant GST-IKK (Invitrogen) and recombinant GST-
TRAF2 (Novus Biologicals) were used. Kinase buffer contained 50 mM Tris (pH 
7.5), 12 mM MgCl2, 1 mM β-glycerophosphate, 100 μM ATP, and 10 μCi γ-32P-
ATP/reaction. Reactions were incubated at 30ºC for 1h, resolved on SDS-PAGE, and 
directly exposed to radiography film. 
 
NF-B reporter assays 
HA1EM and HEK293T cells were transfected with pTRH1-NF-B-Luciferase 
reporter NF-B-luciferase reporter (System Biosciences) in parallel to pRL-SV40-
Renilla (Promega). NF-B activity was measured using the Dual-Glo Luciferase 
assay (Promega) 36h post-transfection. Alternatively, GloResponse NF-B-RE-luc2P 
HEK293T cells (Promega) were transfected as indicated and NF-B activity was 
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measured 36h post-transfection according to the protocol for the One-Glo Luciferase 
assay (Promega). Luciferase values were normalized to renilla values to yield relative 
light units (RLU).  
 
In vitro cell transformation assay 
Growth of NIH 3T3, HA1EM, or HMLE cells in soft agar was determined by plating 
5 X 104 cells in triplicate in 0.4% Noble agar. Microscopic (greater than 100μm in 
diameter) or macroscopic (greater than 1500m in diameter) colonies were counted 
28 d after plating. 
 
 
Viability and proliferation measurements 
Proliferation assays were performed in duplicate using a Vi-Cell counter every 7d for 
14 d and plotted as a function of population doubling (PD) vs. time. PD were defined 
as [log2(cells counted/cells plated)]. 
 
RESULTS 
IKK phosphorylates and binds to TRAF2 
We previously demonstrated IKK phosphorylates and inactivates the tumor 
suppressor CYLD using an integrated proteomic and bioinformatic approach [Chapter 
3, 10]. Although CYLD is one IKK substrate that contributes to cell transformation, 
we found that suppression of CYLD failed to fully inhibit IKK-mediated 
tumorigenicity, suggesting that other IKK effectors contribute to cell transformation. 
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 When we reexamined the list of candidate IKK substrates, we recognized 
that TRAF2, a molecule that plays an essential role in TNF-induced NF-B 
activation, harbors several potential IKK substrate recognition motifs. To test 
whether IKK phosphorylates TRAF2, we performed an in vitro kinase assay using 
recombinant GST-tagged IKK and recombinant GST-tagged TRAF2. We observed 
robust autophosphorylation of IKK and also verified that TRAF2 was strongly 
phosphorylated by IKK (Figure 4.1A). To confirm that IKK phosphorylates TRAF2 
in vivo, we first co-expressed a Myc-epitope tagged TRAF2 and either GST-tagged 
IKK or kinase-inactive IKK K38A in human embryonic kidney epithelial cells 
(HEK293T). We then isolated TRAF2 immune complexes and found that TRAF2 
was phosphorylated by wildtype IKK in a kinase-dependent manner using an IKK 
phospho- substrate antibody (Figure 4.1B). These observations demonstrate that 
IKK phosphorylates TRAF2 both in vitro and in vivo. 
We next examined whether IKK interacts with TRAF2. In the HEK293T 
cells co-expressing Myc-TRAF2 and GST-IKK or the kinase inactive mutant GST-
IKK K38A, we found that both WT and K38A IKK and TRAF2 formed a readily 
detectable complex (Figure 4.1B). To confirm that this interaction occurs under 
conditions where IKK expression induces cell transformation, we determined 
whether IKK interacts with endogenous TRAF2 in immortal but non-tumorigenic 
human embryonic kidney cells (HEK) expressing hTERT, SV40 Large T and small t 


































Figure 4.1. IKK phosphorylates TRAF2 in vitro and in vivo 
 (A) In vitro phosphorylation of TRAF2 by IKK. Kinase assay using recombinant 
GST-IKK and GST-TRAF2. Two concentrations (0.9 g and 1.8 g) of GST-
TRAF2 were phosphorylated by GST-IKK. (B) Phosphorylation of TRAF2 by IKK 
in HEK293T cells. Myc–TRAF2 immune complexes were isolated from HEK293T 
cells expressing the indicated proteins and analyzed by immunoblot with antibodies 




cells, we isolated endogenous TRAF2 immune complexes and verified that IKK and 
TRAF2 interact (Figure 4.2A). 
TRAF2 has been shown to form a complex with the ubiquitin ligase CIAP1, 
the TRAF family member-associated NF-B activator (TANK) and TBK1, a non-
canonical IKK closely related to IKK [14, 15]. This complex acts as a scaffold that 
facilitates the activation of NF-B signaling. To determine whether CIAP1 and 
TANK were also present in the complex formed by IKK and TRAF2, we isolated 
TRAF2 immune complexes from HA1EM cells expressing V5-tagged TRAF2 and 
detected endogenous IKK, TBK1, CIAP1 and TANK (Figure 4.2B). We also 
assessed whether this complex forms in IKK-transformed HA1EM cells. 
Specifically, we isolated TANK immune complexes from HA1EM cells and HA1EM 
cells stably expressing Flag-epitope tagged IKK (HA1EM-F-IKK) and found a 
complex composed of endogenous TANK, TRAF2, CIAP1, TBK1 and IKK (Figure 
4.2C).  
Overexpression of IKK increased the abundance of the complex, suggesting 
that IKK drives the recruitment of these components. To further verify these 
observations, we examined whether this complex exists in breast cancer cells that 
depend on IKK for survival. Specifically, we confirmed that the IKK-TANK-
TRAF2-CIAP1-TBK1 is present in MCF-7 cells (Figure 4.2D). These findings 


















Figure 4.2. IKK forms a complex with TRAF2, CIAP1, TANK and TBK1 
(A) Endogenous interaction between IKKε and TRAF2 in IKKε -transformed cells. 
TRAF2 immune complexes were isolated from HA1EM cells using a murine (M) 
monoclonal antibody and analyzed by immunoblot with IKKε and rabbit (R) TRAF2 
antibodies. (B) TRAF2, IKKε, TANK, CIAP1 and TBK1 form a complex. V5 
immune complexes were isolated from HA1EM cells transduced with V5-GFP or V5-
TRAF2 and analyzed by immunoblot with antibodies specific for V5, TANK, CIAP1, 
IKKε, or TBK1. Murine immunoglobulin (mIg) was used for control 
immunoprecipitations. (C) Complex formation of endogenous TANK, TRAF2, and 
IKKε. TANK immune complexes were isolated from HA1EM cells transduced with 
control vector or F-IKKε and analyzed by immunoblot with antibodies specific for 
IKKε, TRAF2, and TANK. Rabbit Ig (rIg) was used for control 
immunoprecipitations. (D) Complex formation of endogenous TANK, TRAF2, IKKε 
and TBK1 in MCF-7 cells. TANK immune complexes were isolated from MCF-7 
breast cancer cells and analyzed by immunoblot with antibodies specific for IKKε, 
TRAF2, TBK1 and TANK. Rabbit Ig (rIg) was used for control 
immunoprecipitations. 
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IKK phosphorylates TRAF2 on Ser11 to facilitate NF-B activation 
 To identify TRAF2 residue(s) that are phosphorylated by IKK, we surveyed 
the TRAF2 protein sequence for serine residues that correspond to the IKK kinase 
recognition motif [10]. This motif consists of a central serine phosphorylation site 
neighbored by a leucine residue at the +1 position and hydrophobic residues at the -2 
and +3 positions (Figure 4.3A). We found five TRAF2 serine residues at positions 11, 
102, 274, 327 and 408 that matched this motif. 
 We then interrogated whether these sites are phosphorylated by IKK by 
generating serine to alanine substitutions for each putative target serine residue. After 
coexpressing GST-IKK with wildtype or each of these TRAF2 mutants in HEK293T 
cells, we isolated TRAF2 immune complexes and found that each of the TRAF2 
mutants retained the ability to bind IKK (Figure 4.3B). However, when we 
examined the phosphorylation status of wildtype and mutant TRAF2, we found that 
IKK phosphorylated TRAF2 S102A, TRAF2 S274A, TRAF2 S327A and TRAF2 
S408A comparably to wildtype TRAF2. In contrast, we found that IKK failed to 
phosphorylate TRAF2 S11A (Figure 4.3B), indicating that IKK targets TRAF2 
Ser11 for phosphorylation. 
 To examine whether IKK phosphorylates endogenous TRAF2, we 
investigated the consequences of manipulating IKK expression on the 
phosphorylation of TRAF2 at Ser11. First, we suppressed IKK in HA1EM cells and 
several breast cancer cell lines that depend on IKK for tumorigenic growth (MCF-7, 
ZR-75-1 and MDA-MB-453). We introduced two distinct IKK-specific shRNAs in 






Figure 4.3. IKK phosphorylates TRAF Ser11. 
(A) IKKε recognition motif and candidate TRAF2 serine residues that match the 
motif. Highlighted residues (red) indicate a match to the recognition motif. (B) IKKε 
binds to and phosphorylates TRAF2 at Ser 11. HEK293T cells were transfected as 
indicated. Myc-TRAF2 immune complexes were isolated and analyzed with 







(Ser11)-specific antibody [16]. Suppression of IKK in HA1EM cells with these two 
IKK-specific shRNAs resulted in a 3.6- and 4.2-fold decrease in the levels of 
TRAF2 Ser11 phosphorylation, respectively (Figure 4.4A). We also observed a 
decrease in TRAF2 Ser11 phosphorylation after IKK suppression in MCF-7, ZR-75-
1 and MDA-MB-453 breast cancer cells (Figure 4.4B). To corroborate these 
observations, we determined whether expression of IKK promoted an increase in 
TRAF2 phosphorylation at Ser11. We previously showed that the introduction of F-
IKK or Myristoylated, Flag-epitope tagged IKK (MF-IKK) transforms HA1EM 
cells [9]. When we assessed the levels of phosphorylated TRAF2 in HA1EM 
expressing F-IKK or MF-IKK, we found a 2.3 and 4.8-fold increase respectively in 
TRAF2 Ser11 phosphorylation (Figure 4.4C). These observations confirmed that 
IKK phosphorylates TRAF2 at Ser11 in vivo and suggest that this activity is 
important for cell transformation. 
 To elucidate the functional consequences of IKK-mediated TRAF2 Ser11 
phosphorylation, we assessed whether this activity modulates NF-B activation. 
Using GloResponse NF-κB-RE-luc2P HEK293T cells (Promega), a cell line that 
stably expresses a NF-B luciferase reporter, we found that expression of either IKK 
or TRAF2 induced a 5- fold or 14-fold increase in NF-B activity respectively 
(Figure 4.5A, [9, 16]). In contrast, both kinase inactive IKK  K38A and TRAF2 
S11A failed to promote NF-B activation (Figure 4.5A). To evaluate the effects of 
IKK and TRAF2 induced NF-B activation in cells that are readily transformed by  
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Figure 4.4. IKK phosphorylates TRAF2 in vivo 
(A and B) Effects of suppressing IKKε on TRAF2 Ser11 phosphorylation. 
Immunoblot of phospho-TRAF2 (Ser11) in HA1EM cells(A) or in MCF-7, ZR-75-1, 
and MDA-MB-453 breast cancer cells(B) transduced with shLacZ or shLuc controls 
or two IKKε-specific shRNAs (shIKKε #3 and shIKKε #5). Total IKKε, TRAF2 and  
-actin expression are shown. Densitometry analysis for is shown in the lower panel. 
(C) TRAF2 Ser11 phosphorylation in IKKε -transformed HA1EM cells. Immunoblot 
was performed as in (A) on HA1EM cells expressing a control vector, F-IKKε, MF-





IKK, we performed NF-B luciferase reporter experiments in HA1EM cells. 
Expression of either IKK or TRAF2 alone in HA1EM cells induced a 2.7-fold 
increase in NF-B activity as compared to the activity measured in cells expressing a 
control vector (Figure 4.5B). In contrast, coexpression of IKK and wildtype TRAF2 
resulted in a 7-fold increase in NF-B activity. Since we failed to observe a similar 
increase in IKK-mediated NF-B activation by coexpressing IKK and TRAF2 
S11A, we concluded that the increased NF-B activity was due to IKK -mediated 
phosphorylation of TRAF2 at Ser11. In consonance with these findings, we found 
that wildtype TRAF2 induced the expression of NF-B target genes BIRC3 and IL-6 
by 2.5 and 4.3 fold respectively in MCF-7 cells, whereas TRAF2 S11A did not 
significantly activate these NF-B regulated genes (Figure 4.5C). Collectively, these 
results suggest that IKK-mediated TRAF2 Ser11 phosphorylation facilitates 
downstream NF-B activation.  
 
IKK-induced TRAF2 Ser11 phosphorylation promotes TRAF2 Lys63-linked 
ubiquitination 
 Ubiquitination plays a key role in NF-B activation [17, 18]. For example, Lys48-
linked ubiquitination mediates proteasomal degradation of IB that is essential for 
nuclear translocation of NF-B transcription factors [19]. In addition, modification of 
NF-B regulators  including TRAFs, RIP and NEMO with Lys63-linked ubiquitin 
chains facilitates the formation of a protein platform consisting of the canonical IKKs  
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 Figure 4.5.  IKK promotes TRAF2 induced NF-B activation 
(A) IKKε and TRAF2 induced NF-B activation. GloResponse NF-κB-RE-luc2P 
HEK293T luciferase reporter cells were transfected as indicated and raw light unit 
(RLU) activity was normalized to activity observed with control vector. (B) IKK-
induced NF-B activation in the presence of wildtype TRAF2 and TRAF2 S11A. 
HA1EM cells were cotransfected as indicated with SV40-renilla, and a NF-B 
luciferase. Raw light unit (RLU) activity was normalized to activity observed with 
control vector. Results reported as mean ± SD of three experiments. (C) Change in 
expression of selected NF-B regulated genes in MCF-7 cells harboring either a 
control vector, TRAF2 or TRAF2 S11A 
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as well as the IKK kinases, TAK1, RIP1 and other scaffolding molecules [17, 18]. 
Prior work has shown that TRAF2 is modified by both Lys63- and Lys48-linked 
ubiquitination, and that these modifications regulate the recruitment of the IKK 
complex and downstream NF-B activation [20]. We reasoned that TRAF2 
phosphorylation by IKK may regulate TRAF2 ubiquitination and evaluated total 
ubiquitination of TRAF2 in the presence and absence of IKK. We coexpressed Myc-
TRAF2, HA-Ubiquitin, and either GST-IKK or GST-IKK K38A in HEK293T 
cells. From these cells, we isolated TRAF2 immune complexes and determined 
whether TRAF2 was ubiquitinated. We found that expression of IKK dramatically 
increased TRAF2 ubiquitination in a kinase-dependent manner, suggesting that 
phosphorylation of TRAF2 by IKK was required for TRAF2 ubiquitination (Figure 
4.6A). We made similar observations in both IKK-transformed human mammary 
epithelial cells (HMLEM) and HA1EM cells stably expressing Flag-TRAF2. In both 
cases, when we isolated TRAF2 immune complexes, we found ubiquitin-containing 
species in cells overexpressing IKK (Figure 4.6B and C). These observations 
indicate that IKK promotes TRAF2 ubiquitination in transformed cells. 
  To confirm that IKK regulates TRAF2 ubiquitination specifically through 
phosphorylation of Ser11, we evaluated the ubiquitination status of both wildtype 
TRAF2 and TRAF2 S11A. When we expressed wildtype Myc-TRAF2 in HEK293T 
cells and performed a TRAF2 immunoblot, we observed a series of high molecular 
weight species that correspond to TRAF2 ubiquitination. In contrast, Myc-TRAF2 
S11A expression results in a substantial decrease in TRAF2 ubiquitination. 
Interestingly, a catalytically inactive form of TRAF2, in which the E3 ligase RING  
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 Figure4.6 IKKε promotes TRAF2 ubiquitination 
(A) Total TRAF2 ubiquitination in HEK293T cells cotransfected as indicated with 
HA-Ub. Myc-TRAF2 immune complexes were isolated and analyzed by immunoblot 
with an HA antibody. (B) Endogenous TRAF2 ubiquitination in HMLEM cells 
expressing a control vector, MF-IKKε and F-IKKε. TRAF2 immune complexes were 
isolated and analyzed by immunoblot with antibodies specific for ubiquitin, TRAF2 
and IKKε. (C) Endogenous TRAF2 ubiquitination in HA1EM cells expressing a 
control vector and F-IKKε. TRAF2 immune complexes were isolated and analyzed 
by immunoblot with antibodies specific for TRAF2 and IKKε. 
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domain  of the protein has been deleted (RING), did not undergo ubiquitination at 
all., suggesting that the sites of TRAF2 ubiquitination are found within the RING 
domain of the protein (Figure 4.7A). In agreement with our prior findings, we found 
that coexpression of V5-IKK and Myc-TRAF2 expression induces in a dramatic 
increase in TRAF2 Ser11 phosphorylation. Moreover, the phosphorylated TRAF2 is 
strongly ubiquitinated in the presence of IKK (Figure 4.7B). In contrast, kinase 
inactive IKK K38A failed to promote either phosphorylation or ubiquitination of 
TRAF2. These findings demonstrate that Ser11 phosphorylation by IKK is important 
for TRAF2 ubiquitination. 
We next determined which type of ubiquitin linkages were affected by 
TRAF2 phosphorylation. Specifically, we co-expressed a HA-tagged ubiquitin mutant 
that only contains Lys63 linkages (HA-Lys63-Ub) and either wildtype IKK or IKK 
K38A in HEK293T cells, isolated HA-Ubiquitin immune complexes, and determined 
whether TRAF2 was present. We found that the expression of wildtype but not kinase 
inactive IKK induced a 3-fold increase in Lys63-linked ubiquitination of TRAF2 
(Figure 4.7C). These observations demonstrate that IKK-induced ubiquitination of 
TRAF2 involves Lys63-linked ubiquitin and is dependent on IKK kinase activity.  
To determine whether TRAF2 Lys63-linked ubiquitination requires Ser11 
phosphorylation, we introduced the Myc-TRAF2 mutants (S11A and S102A) and 
HA-Lys63-Ub in HEK293T cells. We then isolated HA-ubiquitin immune complexes 
and performed an immunoblot analysis of TRAF2. We found robust Lys63-linked 




































Figure 4.7.  IKK promotes Lys63-linked TRAF2 ubiquitination through 
phosphorylation of Ser11 
(A) TRAF2 ubiquitination is dependent on Ser11 phosphorylation. HEK293T cells 
were transfected as indicated. Lysates were analyzed by immunoblot with antibodies 
specific for TRAF2 and -actin. (B) HEK293T cells were transfected as indicated. 
Lysates were analyzed by immunoblot with antibodies specific for TRAF2, IKK and 
pTRAF2 (Ser11). (C) Lys63-linked TRAF2 ubiquitination in the presence of IKKε. 
HEK293T cells were cotransfected as indicated with HA-K63-Ub. 
Immunoprecipitation was performed using an HA antibody followed by immunoblot 
analysis of Myc-TRAF2. Short exposure shows Myc-TRAF2 above IgH (D) Lys63-
linked ubiquitination of wildtype TRAF2 and TRAF2 phosphorylation mutants. HA-
K63-Ub immune complexes were isolated from HEK293T cells cotransfected as 
indicated with HA-K63-Ub and analyzed by immunoblot with a TRAF2 antibody.  
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 evidence of Lys63-linked ubiquitination of TRAF2 S11A (Figure 4.7D). Thus, IKK 
promotes TRAF2 Lys63-linked ubiquitination in a manner that is dependent on Ser11 
phosphorylation. 
 
TRAF2 is essential for IKK-mediated NF-B activation and cell transformation 
Since IKK phosphorylates TRAF2 to promote its Lys63-linked ubiquitination and 
NF-B activation, we investigated whether TRAF2 was essential for IKK-induced 
NF-B activation and transformation. Using two distinct TRAF2-specific shRNA, we 
suppressed TRAF2 expression in HEK293T cells and two IKK-transformed cell 
models, HA1EM and HMLEM cells that stably express IKK. We found that TRAF2 
suppression strongly inhibited IKK-induced NF-B activity (Figure 4.8A) and 
suppressed anchorage-independent colony formation in HA1EM and HMLEM cells 
(Figure 4.8B, C, D and E). These results indicate that TRAF2 is required for 
transformation driven by IKK. 
 To determine whether TRAF2 Ser11 phosphorylation is necessary for IKK-
induced transformation, we generated IKK-transformed HA1EM cells that stably 
express wildtype TRAF2, TRAF2 S11A, and TRAF2 S102A (Figure 4.9A). As 
expected, we found that cells expressing F-IKK showed robust anchorage-
independent growth (Figure 5F). However, expression of TRAF2 S11A inhibited 
anchorage-independent colony growth by 42%, suggesting that this mutant acts as a  
dominantly interfering mutant (Figure 4.9B). These findings demonstrate that 
































Figure 4.8. TRAF2 is required for IKKε-induced NF-B activation and 
transformation 
(A) IKKε -induced NF-B activity following suppression of TRAF2. HEK29T cells 
were cotransfected as indicated with SV40-renilla and a NF-B luciferase reporter. 
Raw light unit (RLU) activity was normalized to activity observed with control 
vector. Results reported as mean ± SD of three experiments. *p = 5.2 x 10-5, 
calculated by a standard t-test. (B) TRAF2 suppression in IKKε -transformed HA1EM 
and HMLEM cells. Immunoblot of TRAF2 and IKKε in control IKKε-transformed 
HA1EM and HMLEM cells following transduction with shTRAF2#1, shTRAF2#2 or 
control shGFP. Results show -actin loading control. (C) Anchorage-independent 
growth of IKKε -transformed HA1EM cells following TRAF2 suppression. Colony 
formation of cells from (B) was analyzed after 28 d. Results reported as mean ± SD 
of three experiments. *p = 4.7 x 10-5, calculated by a standard t-test. (D) Anchorage-
independent growth of IKKε- transformed mammary cells following TRAF2 
suppression. Colony formation of cells from (B) was analyzed after 28 d. Results 









Figure 4.9. TRAF2 Ser11 phosphorylation is required for IKK-mediated 
transformation 
(A) TRAF2 overexpression in IKKε -transformed HA1EM cells. Immunoblot of 
TRAF2 and IKKε in control (vector) HA1EM or HA1EM- F-IKKε cells transduced 
with V5-GFP, V5-TRAF2, V5-TRAF2 S11A, or V5-TRAF2 S102A. Results show -
actin loading control. (B) Anchorage-independent growth of IKKε -transformed cells 
in the presence of TRAF2. Colony formation of cells from (E) were assayed after 28 





IKK-dependent breast cancer cells are also dependent on TRAF2 
 Since TRAF2 is an IKK substrate necessary for IKK-induced transformation, we 
sought to determine whether TRAF2 is essential in IKK-dependent breast cancer cell 
lines. We first measured IKK expression and TRAF2 Ser11 phosphorylation levels 
in several breast cancer cell lines. We identified five lines (BT549, MDA-MB-453, 
ZR-75-1, MCF-7 and T47D) with increased IKK expression that also showed an 
increased level of TRAF2 Ser11 phosphorylation as compared to total TRAF2 levels 
(Figure 4.10A).  In accordance with our prior findings, these cell lines also exhibited 
a decreased proliferative capacity in a long-term proliferation assay when we 
suppressed IKK with two independent IKK-specific shRNA (Figure 4.10B). When 
we suppressed TRAF2 in these IKK–dependent breast cancer cell lines, we observed 
a similar decrease in cell proliferation as well (Figure 4.10B). In contrast, breast 
cancer cell lines that do not depend on IKK expression exhibited no change in 
proliferation after TRAF2 depletion. Together these observations identify TRAF2 as 
an IKK substrate necessary for IKK-induced transformation.   
 133
 
Figure 4.10. TRAF2 is required for IKKε-mediated transformation 
(A) Levels of IKKε, pTRAF2 (Ser11) and total TRAF2 in breast cancer cell lines. 
Immunoblot was performed in the indicated breast cancer cell lines. A ratio of 
pTRAF(ser11)/total TRAF2 was calculated by densitometry and shown in the lower 
panel. (B) Long-term proliferative capacity of cell lines following IKKε and TRAF2 
suppression. Population doubling (PD) of breast cancer cell lines from (A) after 
transduction with shLacZ, shTRAF2#1, shTRAF2#2, shIKK#3 or shIKK#5. Cells 
were assayed for 14 d. Culmulative PDs are shown on the vertical axis, Time in days 




IKK phosphorylates and regulates TRAF2 
 TRAF2 is an adaptor molecule that mediates a series of ubiquitination events 
that facilitate NF-B activation [20] and is itself modified by ubiquitination [17]. 
Recent work indicates that TRAF2 is phosphorylated at various serine residues 
important for NF-B activation [16, 21-23]. In particular, TRAF2 Ser11 
phosphorylation has been previously reported and this activity occurs constitutively in 
some cancer cell lines [16]. Here, we demonstrate that IKK phosphorylates TRAF2 
both in vitro and in vivo. We performed a mutational analysis of five TRAF2 serine 
residues that matched the IKK recognition motif and identified Ser11 as the residue 
on TRAF2 that is phosphorylated by IKK. This activity was necessary for TRAF2 
Lys63-linked ubiquitination, NF-B activation and subsequent transformation.  
 Phosphorylation of TRAF2 at Ser11 is required for TRAF2 Lys63-linked 
ubiquitination. Phosphorylation and subsequent Lys63-linked ubiquitination of 
TRAF2 at serine 11 is necessary for IKK-mediated NF-B activation and 
transformation. Since CIAP1 regulates TRAF2 stability, the interaction of IKK and 
CIAP1 may be involved in the regulation of TRAF2 stability. CIAP1 plays multiple 
roles in promoting TRAF2 ubiquitination, attenuating caspase activation and 
apoptosis, and promoting NF-B activation [15, 24, 25]. Thus, dynamic regulation of 




 IKK regulates both TRAF2 and CYLD 
  We previously demonstrated that IKK regulates the activity of CYLD, a 
tumor suppressor and inhibitor of NF-B signaling [10]. The observations presented 
herein suggest that the phosphorylation of CYLD and TRAF2 by IKK coordinates 
these NF-B regulators to activate NF-B signaling in the context of cell 
transformation. Since TRAF2 is also directly inactivated by CYLD through 
deubiquitination, TRAF2 appears to be a central mediator of IKK transformation 
[26].  
 IKK is amplified and overexpressed in 30% of breast cancers and is an 
essential gene in cells that harbor IKK copy number gain [9]. We have determined 
that TRAF2 also plays an essential role in IKK- driven breast cancers. The 
identification of these dependencies provides multiple therapeutic strategies in 
targeting the NF-B pathway in breast cancer. 
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 In this dissertation, I have investigated the regulation and effectors of the 
breast cancer oncogene, IKK. IKK is required for the survival of the 30% of breast 
cancers that harbor an IKBKE amplification, making IKK an attractive target for 
cancer therapeutics. However, unlike other oncogenes and tumor suppressors such as 
Ras, BRAF and PIK3CA, current activating or protein function-altering mutations 
involving IKK have not yet been identified [1-3]. Thus, it would follow that the 
amplification of IKK itself somehow leads to its aberrant regulation in cancer, 
resulting in its oncogenic function.  
 Prior to its identification as a breast cancer oncogene, IKK was shown to 
serve as activator of interferon signaling in innate immunity. In this context, IKK is 
known to act in complex with TBK1 to phosphorylate IRF3 and IRF7 [4, 5]. In 
addition, as non-canonical IKK proteins, IKK and TBK1 activate NF-B 
signaling[4, 6, 7]. In the context of breast cancer, IKK also activates NF-B 
signaling and, interestingly, this NF-B activity is required for IKK oncogenic 
function [8]. Thus, we sought to define the oncogenic signaling pathway that resulted 
in the aberrant and NF-B-dependent activation of IKK. In my dissertation work, I 
have defined the role of ubiquitination in the regulation of IKK (Chapter 2). In 
addition, through collaborative work, we have also uncovered two novel downstream 
targets of IKK kinase function (Chapters 3 and 4) in the context of oncogenic cell 
transformation. This work, taken together, defines a novel oncogenic signaling 




IKK REGULATION BY K63-LINKED UBIQUITINATION 
 Both degradation-dependent and degradation-independent ubiquitination are 
essential for the proper regulation of specific components in the NF-B pathway [9]. 
Thus, we suspected that IKK was also regulated by ubiquitination. In Chapter 2, I 
found that IKK was indeed regulated by K63-linked degradation-independent 
ubiquitination. I further identified K30 and K401 to be the critical residues of IKK 
modification and found that ubiquitination of IKK at these two residues is required 
for proper IKK oncogenic function. In addition, I identified TRAF2 as a putative E3 
ligase that is responsible for IKK K63-linked ubiquitination in the context of breast 
cancer.  
 Here, I have also identified a possible structural explanation for the 
essentiality of IKK ubiquitination. Ongoing collaborative work with Daqi Tu, 
Michael Eck, Zehua Zhu and David Barbie (in submission) has solved the protein 
crystal structure of TBK1, a close family member of IKK with whom IKK shares 
~65% similarity. This work has found that TBK1 homodimerization is required for 
TBK1 kinase function, downstream IRF3 phosphorylation and NF-B activation.  
Residues K30 and K401 are conserved between IKK and TBK1, and I have found 
that, like IKK, TBK1 is also ubiquitinated on K30 and K401. In the TBK1 protein 
structure, the conserved K30 and K401 residues are found on opposing faces of the 
dormant monomer but become juxtaposed on an exposed face when the catalytically-
active dimer is formed.  Thus, this data suggests that K63-linked ubiquitination of 
IKK and TBK1 at these two critical residues is important for the interface of the 
 142
kinase with other regulatory proteins and binding partners. In future studies, it would 
be interesting and informative to determine which proteins interact with this interface, 
and how these interactions are regulated both in the context of cancer and innate 
immunity.  
Importantly, my work has demonstrated that the K30 and K401 ubiquitination 
defective IKK mutants are still able to bind to the downstream substrate, CYLD. 
This observation makes it unlikely that these mutants disrupt the overall structure of 
IKK. Instead, these data suggest that ubiquitination at K30 and K401 induces an 
allosteric change to regulate kinase activity, or that these mutations affect the 
recruitment of other molecules critical for IKK kinase function. Thus further studies 
are needed to determine the mechanism by which IKK ubiquitination regulates its 
kinase function. 
In my dissertation work, I have also defined a novel role for TRAF2 as an E3 
ligase that modifies IKK with K63-linked ubiquitin chains. TRAF2 is known to 
interact in the same complex with TBK1, cIAP1, and TANK [4, 10]. Previously, 
TRAF2 has been characterized as the E3 ligase that is responsible for RIP1 K63-
linked ubiquitination in the context of the canonical NF-κB pathway [11]. It has also 
been shown that cIAP1 and cIAP2 are capable of catalyzing RIP1 ubiquitination as 
well [12]. Here, I have demonstrated that TRAF2, but not TRAF6, is required for 
IKK ubiquitination and that its RING domain is essential for its function. However, I 
have not extensively surveyed the entire collection of E3 ligases that are capable of 
catalyzing K63-linked ubiquitination. In addition, although the mass spectrometry 
analysis has covered the majority of the internal lysines within IKK (22 out of 34, 
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64.7%) there still remain a set of residues that have not been surveyed. Although I 
have identified two essential residues for IKK ubiquitination and subsequent 
downstream function, K30 and K401, it is certainly possible that there are more 
modified residues that have yet to be studied. Polyubiquitination is a very dynamic 
and often transient form of regulation. The analysis here has identified one particular 
mechanism of IKK regulation by ubiquitination, but more comprehensive work in 
the future will be required in order to define all the residues, ubiquitin linkage types, 
and E3 ligase enzymes that play a role in this complex process. 
 
IDENTIFYING THE DOWNSTREAM TARGETS OF IKK ONCOGENIC 
ACTIVATION 
 In collaborative work, we have used an unbiased peptide screen to define the 
downstream targets of IKK kinase function [13, 14]. Through the use of this screen, 
we have identified two substrates, TRAF2 and CYLD, as effectors of IKK 
oncogenic signaling. 
In Chapter 3, we identified CYLD Ser418 to be a direct phosphorylation 
target of IKK. CYLD is already known to be tumor suppressor whose mutation leads 
to the development of familial cylindromatosis, an autosomal dominant disease 
characterized by the formation of benign skin tumors [15]. We found IKK 
phosphorylation of CYLD at Ser418 to be an inhibitory modification, resulting in 
CYLD loss of function. We determined that CYLD Ser418 phosphorylation is 
essential for IKK-mediated transformation and CYLD deubiquitinase function. 
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 In Chapter 4, we also identified TRAF2 Ser11 to be a direct phosphorylation 
target of IKK. Phosphorylation of TRAF2 at Ser11 results in its activation by K63-
linked ubiquitination. We further determined that TRAF2 phosphorylation at Ser11 is 
essential for IKK-mediated transformation and subsequent NF-B activation. 
 CYLD and TRAF2 have been shown to be essential regulators of normal NF-
B signaling. CYLD is known to associate with and deubiquitinate NEMO, the 
regulatory subunit of the IKK complex, thereby negatively regulating canonical NF-
B activation [16, 17]. TRAF2 has been well-studied to activate the canonical NF-B 
pathway by mediating the signaling between the proinflammatory cytokine receptors 
and the TAK complex, an activator of the canonical IKK complex [9, 18]. Together, 
the activation of TRAF2 and inactivation of CYLD results in the cooperative 
upregulation of canonical NF-B signaling. Previous work has defined IKK-
mediated oncogenic transformation to also be dependent on canonical NF-B 
signaling. Specifically, the introduction of a non-degradable form of IB, known to 
be a super-repressor of canonical NF-B signaling, resulted in the ablation of IKK-
mediated transformation as assessed by soft agar colony formation [8]. Though this 
data was quite striking, it remained unclear why a super-repressor of the canonical 
NF-B pathway would have an effect on the signaling of a non-canonical IKK 
protein. In this dissertation work, we have demonstrated that, in the context of cancer, 
IKK directly activates TRAF2 and inactivates CYLD, two effectors in the canonical 
NF-B pathway. These data not only offer a mechanistic explanation for how IKK 
mediates transformation but, further answer the question about why IKK-mediated 
transformation is dependent on the canonical NF-B pathway. 
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 Importantly, although these studies have shown TRAF2 and CYLD to be 
major contributors towards IKK-mediated transformation, there are several other 
putative IKK substrates that were identified in our unbiased peptide screen that may 
also be IKK effectors. These other substrates may prove not only to be important 
players in IKK-mediated oncogenic function, but also effectors of IKK function in 
innate immunity and NF-B activation. For future studies, identification and 
characterization of these putative IKK substrates may provide further insight into the 
mechanism of IKK function both the context of oncogenic and normal signaling. 
 
DEFINING A FEED-FORWARD NETWORK OF IKK REGULATION 
The intersection of the work presented in this dissertation defines an 
interesting feed-forward network of IKK regulation, illustrated in Figure 5.1. I have 
shown that IKK is positively regulated by TRAF2, a known K63-linked E3 ligase 
[10, 11]. In addition, we have shown that TRAF2 itself is also a downstream target of 
IKK phosphorylation. We have also shown that IKK phosphorylates CYLD, a 
deubiquitinating enzyme (DUB) that removes Lys63 linked ubiquitin chains and acts 
as a negative regulator of NF-B signaling [16, 17, 19]. Interestingly, one direct 
substrate of CYLD deubiquitination is TRAF2. Thus, it would seem that we have 
defined a feed-forward loop in which IKK activation results in further activation of 
TRAF2, leading to even more IKK activation. This mode of regulation may explain 


























Figure 5.1. The IKK oncogenic network in cancer. 
IKK, in dimer form is positively regulated by TRAF2-mediated K63-linked 
ubiquitination at K30 and K401. Activated IKK phosphorylates and activates 
TRAF2 at S11 and inactivates CYLD at S418, resulting in the feed forward activation 
of IKK, activation of aberrant NF-B signaling, and eventual oncogenic 
transformation. 
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However, as we know that IKK is physiologically activated and expressed in 
innate immunity, it is likely that we still do not have a full understanding of how 
IKK operates in the response to viral infections. In the context of innate immunity, 
IKK is tightly regulated in a way that allows it to be turned on and off in the 
presence or absence of viral infection. Thus, there must exist a mode of regulation 
that allows for IKK signaling to be turned off. This could exist in the form of a 
deubiquitinating enzyme that removes IKK K63-linked ubiquitination and thereby 
inhibits it. It is also possible that IKK is negatively regulated by a different kind of 
modification, perhaps an inhibitory phosphorylation or degradation-dependent 
ubiquitination. Alternatively, IKK could also be negatively regulated by a binding 
protein that either sequesters IKK protein to a separate cell compartment or binds to 
IKK in such a way that inhibits IKK K30 and K401 ubiquitination. More studies 
are required to determine how IKK is negatively regulated and to more completely 
define the network of IKK regulation in oncogenic transformation. 
In addition, all of these studies were performed only in the context of IKK 
amplification and overexpression in breast cancer. It is likely that the overexpression 
of IKK results in its dysregulation, allowing it to take on novel functions that are 
usually not active in the normal cell. Thus, the model of specific effectors and modes 
of regulation that we have defined here may not hold true in the context of normal 
IKK function. Therefore, more studies are required to determine if this model of 
IKK regulation and downstream signaling also occurs in the context of interferon 
regulation.  
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IKK AS A THERAPEUTIC TARGET 
 IKK has been shown to be a specific vulnerability for the ~30% of breast 
cancers that harbor an IKBKE amplification or IKK overexpression. This has made 
IKK an attractive candidate as a therapeutic target. However, the significant kinase 
domain homology between IKK and TBK1 makes it unlikely that ATP-competitive 
small molecule inhibitors that inhibit IKK but not TBK1 will be found. Thus, the 
work in this dissertation presents alternative ways to inhibit IKK function. 
Recent work has demonstrated that E3 ligases can also be targeted and 
inhibited by small molecule inhibitors [20]. In particular, small molecule inhibitors of 
the cullin-RING family of E3 ubiquitin ligases have been described [21, 22]. We 
found that TRAF2-mediated K63-linked ubiquitination is essential for IKK kinase 
activity and also that TRAF2 is a downstream target of IKK that functions as an 
IKK oncogenic effector. Thus these observations may identify an alternative 
mechanism to ultimately target IKK therapeutically in the context of human disease. 
 
Taken together, the work that has been presented in this dissertation has 
elucidated a novel regulatory pathway for IKK in the context of breast cancer. We 
have identified key molecular players in the regulation of IKK as well as important 
downstream effectors of IKK function. Though further studies are required to 
complete the picture, the work presented in this dissertation has defined the first 
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